

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer

Jon D. Vogel, M.D.¹ • Seth I. Felder, M.D.² • Anuradha R. Bhama, M.D.³
 Alexander T. Hawkins, M.D.⁴ • Sean J. Langenfeld, M.D.⁵ • Virginia O. Shaffer, M.D.⁶
 Amy J. Thorsen, M.D.⁷ • Martin R. Weiser, M.D.⁸ • George J. Chang, M.D.⁹
 Amy L. Lightner, M.D.³ • Daniel L. Feingold, M.D.¹⁰ • Ian M. Paquette, M.D.¹¹

1 University of Colorado, Aurora, Colorado

2 Moffitt Cancer Center, Tampa, Florida

3 Cleveland Clinic, Cleveland, Ohio

4 Vanderbilt University, Nashville, Tennessee

5 University of Nebraska, Omaha, Nebraska

6 Emory University, Atlanta, Georgia

7 Colon and Rectal Surgery Associates, Minneapolis, Minnesota

8 Memorial Sloan Kettering Cancer Center, New York, New York

9 MD Anderson Cancer Center, Houston, Texas

10 Rutgers University, New Brunswick, New Jersey

11 University of Cincinnati, Cincinnati, Ohio

The American Society of Colon and Rectal Surgeons (ASCRS) is dedicated to ensuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Clinical Practice Guidelines Committee is composed of society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This committee was created to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus and develop clinical practice guidelines based on the best available evidence. While not proscriptive, these guidelines provide information on which decisions can be made and do not dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these

guidelines. These guidelines should not be deemed inclusive of all proper methods of care nor exclusive of methods of care reasonably directed toward obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all the circumstances presented by the individual patient.

STATEMENT OF THE PROBLEM

The American Cancer Society estimated that roughly 105,000 Americans would be diagnosed with colon cancer and 43,000 with rectal cancer, and that 53,200 deaths would be attributed to these cancers in the year 2020.¹ In the United States, colorectal cancer remains the third most common cancer and the third most common cause of cancer-related death.² Approximately nine of 10 patients with colorectal cancer are diagnosed at 50 years of age or older. While the incidence and mortality rate of colorectal cancer are declining for individuals older than 50 years of age, both are on the rise for those younger than 50.¹ The treatment of patients with colon cancer is largely guided by the stage at presentation, emphasizing the importance of a comprehensive strategy for diagnosis, evaluation, and treatment. Surgery is the primary treatment for most patients with colon cancer, while chemotherapy is used most commonly in the adjuvant setting. In the United States cohort of the international CONCORD-2 study, five-year net (cancer-specific) survival was 90%, 70%, and 14% among those with localized, regional, or distant distribution of their colon cancer, respectively.³

Earn Continuing Education (CME) credit online at cme.lww.com. This activity has been approved for AMA PRA Category 1 credit.TM

Funding/Support: None reported.

Financial Disclosures: None reported.

Correspondence: Ian M. Paquette, M.D., 2123 Auburn Ave #524, University of Cincinnati, Cincinnati, OH 45219. Email: ian.m.paquette@gmail.com

Dis Colon Rectum 2022; 65: 148–177

DOI: 10.1097/DCR.0000000000002323

© The ASCRS 2021

Colorectal cancer screening, bowel preparation, hereditary colon cancer, enhanced recovery pathways, surveillance and survivorship after curative treatment, and prevention of thromboembolic disease, while relevant to the management of patients with colon cancer, are beyond the scope of these guidelines and are addressed in other American Society of Colon and Rectal Surgeons (ASCRS) guidelines.⁴⁻⁹

METHODS

This guideline is based on the previous colon cancer parameter published in 2017.¹⁰ Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded recommendations (Table 1). The literature searches were performed with PubMed using a combination of specialty-specific journal titles (Appendix 1, Supplemental Digital Content 1, <http://links.lww.com/DCR/B798>) organized under the subject headings of Gastroenterology, Imaging, Oncology and General Medicine, and Surgery, and the Medline Subject Heading (MeSH) “colorectal neoplasm” combined with the search limits of “journal article” or “guideline” or “controlled clinical trial” or “clinical trial” or “clinical study” or “meta-analysis” or “multicenter study” or “observational study” or “practice guideline” or “randomized controlled trial” or “systematic review,” and the additional search limits of human studies, English language, and adults, and were limited to citations included in searches limited to the date range of April 8, 2015, to April 4, 2021. Additional subject-specific searches were performed with the PubMed search terms/phrases: 1) “incomplete colonoscopy” and 2) “conversion AND colorectal AND liver,” both limited to English language, journal article, and date range of August 6, 2015, to April 4, 2021, and 3) “Oncotype DX OR coloprint OR ColDx OR ctDNA OR circulating tumor DNA AND colon cancer,” limited to English language and journal article, with a date range of January 1, 2009, to June 27, 2021. An Embase query, inclusive of publication years 2017 to 2020, completed on December 2, 2020, with exclusion of titles also included in Medline/PubMed, resulted in 241 unique titles that were screened and resulted in the inclusion of 10 additional titles for the qualitative synthesis phase of the literature review. An additional 35 titles were identified from embedded references. These searches yielded a total of 7958 unique citations. A professional medical librarian provided consultation for the literature searches. The citations were then reviewed by the authors who selected the citations that they considered to be most relevant to the Clinical Practice Guideline. After screening and secondary and tertiary reviews, a total of 1921 individual citations were selected for potential inclusion in the Clinical Practice Guidelines (Appendix 2, Supplemental Digital Content 2, <http://links.lww.com/DCR/B799>). Emphasis was placed on prospective trials, meta-analyses, systematic reviews, and practice guidelines. Peer-reviewed

observational studies and retrospective studies were included when higher quality evidence was insufficient. Ultimately, a total of 328 unique citations were included in the reference list. The final source material used was evaluated for methodological quality, the evidence base was examined, and a treatment guideline was formulated by the subcommittee for this guideline. A final grade of recommendation was assigned using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system (Table 2).¹¹ When agreement was incomplete regarding the evidence base or treatment guideline, consensus from the committee chair, vice chair, and two assigned reviewers determined the outcome. Members of the ASCRS practice guidelines committee worked in joint production of these guidelines from inception to final publication. Recommendations formulated by the subcommittee were reviewed by the entire Clinical Practice Guidelines Committee. The manuscript was additionally reviewed and edited by two ad hoc committee members (M.R.W. and G.J.C.). The submission was then approved by the ASCRS executive council and peer-reviewed in *Diseases of the Colon and Rectum*. In general, each ASCRS Clinical Practice Guideline is updated approximately every five years. No funding was received for preparing this guideline, and the authors have declared no competing interests related to this material. This guideline conforms to the Appraisal of Guidelines for Research and Evaluation (AGREE) checklist.

EVALUATION AND RISK ASSESSMENT

1. **A cancer-specific history should be obtained including disease-specific symptoms, past medical and family history, physical examination, and perioperative medical risk. Routine laboratory values, including carcinoembryonic antigen (CEA) level, should be obtained. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.**

Sporadic, familial (ie, no identifiable germ-line mutation), and hereditary (ie, Lynch syndrome, familial adenomatous polyposis, and *MYH*-associated polyposis) types of colorectal cancer account for approximately 65%, 30%, and <5% of new colorectal cancers in the United States, respectively.¹² The personal and family history should include documentation of premalignant lesions and cancers, age of diagnosis, and the lineage of affected first- and second-degree relatives. Patients should be asked about known hereditary cancer predisposition syndromes, previous genetic testing, and family ancestry/ethnicity that may be relevant.¹³ Patients with findings suggestive of an inherited susceptibility should be referred for genetic counseling given that the results may impact surgical decision-making. Among colon cancer patients younger than 50 years, up to one-third may carry a germline mutation associated with colon cancer; these patients often do

TABLE 1. What Is New in the 2021 ASCRS Colon Cancer Clinical Practice Guidelines

2021 New Recommendations	
Neoadjuvant therapy	#6. When neoadjuvant therapy is not included in the treatment plan, curative intent colectomy should be performed without unneeded delay. Grade of recommendation: strong recommendation based on low quality evidence, 1C.
Neoadjuvant therapy	#12. In patients with locally advanced colon cancer, neoadjuvant chemotherapy or radiotherapy can result in tumor regression and may facilitate margin-negative excision of locally advanced cancers. Grade of recommendation: weak recommendations based on moderate-quality evidence, 2B
Multidisciplinary discussion	#21. The treatment of patients with resectable stage IV colon cancer should be individualized and based on a comprehensive multidisciplinary discussion. Grade of recommendation: strong recommendation based on moderate quality evidence, 1B.
Resectable liver metastasis	#22. Patients with initially resectable colon cancer liver metastasis, an individualized decision on neoadjuvant chemotherapy followed by surgical resection or up-front surgery. Grade of recommendation: weak recommendation based on moderate-quality evidence, 2B.
Unresectable liver metastasis	#23. Patients with initially unresectable colon cancer liver metastasis should be considered for neoadjuvant chemotherapy to attempt to convert to resectability. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.
Hepatic artery infusion of chemotherapy	#24. Hepatic artery infusion of chemotherapy combined with systemic chemotherapy or immunotherapy may increase resectability of colon cancer liver metastasis, but should only be performed in centers with the appropriate expertise. Strong recommendation based on moderate-quality evidence, 1B.
Combined or staged liver resection	#25. In patients with colon cancer and resectable liver metastasis, a single “combined” operation is generally recommended for relatively low complexity operations and sequential or “staged” operations are generally recommended for higher complexity cases. Grade of recommendation: weak recommendation based on moderate quality evidence, 2B.
Lung metastasis	#26. In patients with resectable colon cancer lung metastasis, resection of the lung lesions should be considered as it may prolong survival. Weak recommendation based on moderate-quality evidence, 2B.
Mismatch repair	#32. In patients with stage IV (dMMR or MSI-H colon cancer, immunotherapy with antibody to PD-L1 or PD-1 should be considered. Strong recommendation based on high quality evidence, 1A
Timing of adjuvant chemotherapy	#33. In general, and if possible, adjuvant chemotherapy should be started within 8 weeks of colon resection. Grade of recommendation: strong recommendation based on moderate quality evidence, 1B
Multigene assays	#34. The use of multigene assays, CDX2 expression analysis, and ctDNA may be used to complement multidisciplinary decision-making for patients with stage II or III colon cancer. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.
2021 Updated Recommendations	
PET/CT	#4. PET/CT is generally not recommended for routine colon cancer staging but may be useful in surgical decision-making for patients with stage IV disease. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.
T4b cancers	#10. For resectable colon cancers that adhere to or invade adjacent organs and are being treated with curative intent, complete and en bloc resection with negative margins is recommended. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.
Oophorectomy	#11. Oophorectomy is typically advised for grossly abnormal ovaries or contiguous extension of colon cancer, but routine prophylactic oophorectomy is not recommended. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.
Malignant polyp	#15. For patients with a “malignant polyp,” either endoscopic excision or oncological resection may be appropriate, and is dependent largely on polyp histopathological features and completeness of excision. Grade of recommendation: strong recommendation based on moderate quality evidence, 1B.
Obstructing left-side colon cancer	#17. For patients with obstructing left-sided colon cancer and curable disease, endoscopic stent decompression, or diverting colostomy, with interval colectomy, are generally preferable to emergent colectomy. Grade of recommendation: strong recommendation based on moderate quality evidence, 1B.
Cancer perforation	#18. In the setting of perforation or impending perforation of the colon, resection following established oncological principles with a low threshold for performing a staged procedure is recommended when feasible. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.
Cytoreductive surgery	#27. In patients with resectable colorectal cancer peritoneal metastases, cytoreductive surgery with or without intraperitoneal chemotherapy should be considered as part of a multimodality treatment plan. Strong recommendation based on moderate quality evidence, 1B.
Stage IV with asymptomatic primary tumor	#28. In patients with incurable stage IV colon cancer and an asymptomatic primary colon cancer, systemic chemotherapy is recommended as the initial treatment. Grade of recommendation: strong recommendation based on moderate quality evidence, 1B.
Obstructing colon cancer in palliative setting	#29. In patients with an obstructing colon cancer and incurable metastatic disease, or in other scenarios in which palliation is preferred over an attempt at cure, endoscopic stent placement or fecal diversion is preferable to colectomy when life expectancy is <1 year. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B
Stage II and adjuvant chemotherapy	#30. In patients with microsatellite stable/mismatch repair proficient stage II colon cancer and obstruction, or perforation, or <12 lymph nodes in the resection specimen, or poor differentiation, or lymphovascular invasion, or perineural invasion, or high-level tumor budding, adjuvant chemotherapy may offer a survival benefit. Weak recommendation based on moderate quality evidence, 2B

(Continued)

TABLE 1. What Is New in the 2021 ASCRS Colon Cancer Clinical Practice Guidelines (Continued)

2017 Recommendations Excluded	
Sentinel lymph nodes	SLN mapping for colon cancer does not replace standard lymphadenectomy. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B. A recommendation on this technique was excluded as its use has not been broadly adopted for clinical practice.
Minimally invasive surgery	Hand-assisted laparoscopic and robotic surgical techniques for right colon cancer result in oncological outcomes that are equivalent to open or straight laparoscopic techniques. Strong recommendation based on moderate-quality evidence, 1B. In 2021, hand-assisted laparoscopic and robotic colectomy techniques were included in recommendation #13: When expertise is available, a minimally invasive approach to elective colectomy for colon cancer is preferred. Grade of recommendation: strong recommendation based on high-quality evidence, 1A.

ctDNA = circulating tumor DNA; dMMR = mismatch repair deficient; MSI-H = microsatellite high; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death-ligand 1; PET = positron emission tomography; SLN = sentinel lymph node

TABLE 2. The GRADE System - Grading Recommendations

	Description	Benefit vs risk and burdens	Methodologic quality of supporting evidence	Implications
1A	Strong recommendation, High-quality evidence	Benefits clearly outweigh risk and burdens or vice versa	RCTs without important limitations or overwhelming evidence from observational studies	Strong recommendation can apply to most patients in most circumstances without reservation
1B	Strong recommendation, moderate quality evidence	Benefits clearly outweigh risk and burdens or vice versa	RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or exceptionally strong evidence from observational studies	Strong recommendation, can apply to most patients in most circumstances without reservation
1C	Strong recommendation, low- or very low- quality evidence	Benefits clearly outweigh risk and burdens or vice versa	Observational studies or case series	Strong recommendation but may change when higher-quality evidence becomes available
2A	Weak recommendation, high-quality evidence	Benefits closely balanced with risks and burdens	RCTs without important limitations or overwhelming evidence from observational studies	Weak recommendation, best action may differ depending on circumstances or patients' or societal values
2B	Weak recommendations, moderate quality evidence	Benefits closely balanced with risks and burdens	RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or exceptionally strong evidence from observational studies	Weak recommendation, best action may differ depending on circumstances or patients' or societal values
2C	Weak recommendation, low- or very low- quality evidence	Uncertainty in the estimates of benefits, risks, and burden; benefits, risk and burden may be closely balanced	Observational studies or case series	Very weak recommendations; other alternatives may be equally reasonable

GRADE = Grades of Recommendation, Assessment, Development, and Evaluation; RCT = randomized controlled trial. Adapted from Guyatt G, Guterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. *Chest*. 2006;129:174-181.¹¹ Used with permission.

not have a clinical history that is typically associated with an identified hereditary cancer syndrome, supporting the recommendation that germline testing should be strongly considered for all young-onset colon cancer patients.¹⁴ Guidelines on the management of patients with inherited colorectal cancer have been previously published by the society.^{6,7} In keeping with the National Cooperative Cancer Network (NCCN) guidelines, all newly diagnosed colon cancers should be evaluated for microsatellite instability (MSI) or mismatch repair protein (MMR) expression.¹⁵

Colon cancer may be asymptomatic or heralded by symptoms of fatigue, blood in the stool, abdominal pain, changes in bowel habits, or obstructive symptoms. Recent retrospective, single-institution, American studies have reported that more than 75% of colon cancer diagnoses occurred after development of symptoms, and

symptomatic cancers were associated with more advanced disease compared with cancers that were identified during screening colonoscopy.^{16,17} Similar results, with nearly 70% of newly diagnosed cancers presenting with symptoms, were reported in a 2016 German population-based study.¹⁸

Patients' medical fitness and nutritional status should be assessed to guide perioperative management and identify opportunities for optimization before surgery. Inquiry about alcohol consumption and smoking is also advised, as these habits have been shown to both increase the risk of developing colorectal cancer and also the risk of postoperative complications.¹⁹⁻²² Early mortality is infrequent among resected colon cancer patients but is more prevalent among patients with advanced age and an Eastern Cooperative Oncology Group performance status ≥ 2 .^{23,24} Frail patients may benefit from preoperative,

multimodality optimization (ie, prehabilitation), although the beneficial effect on postoperative complications and survival has not been firmly established.^{25,26}

Physical examination should include assessment for an abdominal mass or surgical scars, which may influence diagnostic and treatment-related decisions. Routine serum laboratory evaluation should include a complete blood count, liver function tests, and a chemistry panel. A carcinoembryonic antigen (CEA) level should be obtained before elective surgery for colon cancer to establish a baseline value that is prognostic for recurrence and survival, and to provide a reference value for use during surveillance.²⁷ A multivariate analysis of more than 130,000 patients included in the National Cancer Database indicated that preoperative CEA is an independent predictor of overall survival in patients with stage I to III colon cancer.²⁸ Patients with an elevated CEA had a 62% increase in the hazard of death compared with patients with a normal preoperative CEA. Although preoperative CEA level is an independent prognostic factor, the optimal cutoff value to best determine prognostic significance is not clear.^{29–32} In stage IV colorectal cancer, a decrease in CEA in response to treatment with chemotherapy has been associated with improved survival.³³

2. Before colectomy, histologic confirmation of invasive adenocarcinoma should be established and, when feasible, the entire colorectal mucosa should be evaluated for synchronous pathology. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.

When possible, the histologic diagnosis of colon cancer should be confirmed before elective surgical resection because benign processes such as diverticulitis or inflammatory bowel disease may appear grossly similar to the endoscopic or radiographic appearance of colon cancer. Colonoscopy is the preferred evaluation method under these circumstances because it offers a therapeutic opportunity to treat synchronous polyps. Endoscopic biopsy may be nondiagnostic or incongruent with the clinical impression of invasive adenocarcinoma due to sampling error, in which case repeat endoscopic biopsy may be performed in the appropriate clinical circumstance. Lesions concerning for malignancy, but without histologic confirmation (eg, possible sampling error), that are not amenable to endoscopic removal warrant oncological resection. When feasible, a complete evaluation of the colorectal mucosa is advised before surgery to detect synchronous cancers, which are reported to be present in 4% of patients with stages I to III sporadic colon cancer.³⁴ Complete examination of the colorectal mucosa can also identify synchronous adenomas that are present in 30% to 50% of patients.^{35,36} Endoscopic tattooing with documentation of tattoo location (ie, distal or proximal to the tumor) should be performed routinely to facilitate intraoperative localization.

In patients with a proximal cancer that cannot be passed with a colonoscope in whom an oncological resection would include the entire proximal colon (eg, obstructing distal ascending colon cancer), there is generally no need to examine the more proximal colon before colectomy. Alternatively, for patients with an endoscopically obstructing distal colon cancer (eg, sigmoid colon cancer) in whom oncological resection would spare the proximal colon, CT colonography or Fluro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) may be helpful. CT colonography is highly accurate for detecting synchronous advanced neoplasia (ie, high-grade or large adenoma or cancer) has a sensitivity of 94%, and is reported to affect the surgical plan in 2% to 21% of patients.^{37–39} FDG PET/CT may also be sufficient to exclude proximal synchronous neoplasia, with a negative predictive value for advanced adenoma and colon cancer of 93% and 100%, respectively.⁴⁰ Alternatively, intraoperative colonoscopy to detect synchronous lesions is feasible and safe after resection of the tumor and restoration of intestinal continuity or creation of a colostomy.^{41–43} Postoperative colonoscopy is another option for patients in whom preoperative or intraoperative evaluation of the colon was not possible or adequate.⁴⁴ Contrast enema studies have a relatively low yield for the detection colorectal mucosal pathology and therefore are generally not recommended.⁴⁵

STAGING OF COLON CANCER

3. CT of the chest, abdomen, and pelvis with oral and intravenous contrast or noncontrast CT of the chest and abdominal MRI are recommended for colon cancer staging. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

CT scan of the chest, abdomen, and pelvis with intravenous iodinated and oral contrast is recommended before the elective surgical resection of colon cancer.^{15,46} Preoperative CT imaging permits the detection of synchronous metastases, which often requires a change in the treatment strategy and may also alter the operative plan. While the yield of chest CT in detecting colorectal cancer lung metastasis is low (6%–8%), its superiority to standard chest x-ray and ability to detect indeterminate lesions that may demonstrate malignant progression on serial examinations support its use under these circumstances.^{47–50} In patients with an allergy or other contraindication to the use of iodine contrast dye, a PET/CT or noncontrast chest CT with an MRI of the abdomen and pelvis are recommended alternatives.^{51,52} Indeterminate liver lesions identified on CT should generally be further investigated by MRI with diffusion-weighted imaging.^{46,53–56}

4. Positron emission tomography (PET)/CT is generally not recommended for routine colon cancer staging, but may be useful in surgical decision-making for patients with stage IV disease. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

Prospective studies have not demonstrated superiority of PET/CT over standard intravenous contrast-enhanced CT in the detection of colorectal liver or peritoneal metastasis.^{51,57,58} At present, it is not clear if PET/CT offers an advantage to contrast-enhanced CT for the detection of colon cancer lung metastasis.⁵⁹ Both the National Cooperative Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) do not recommend PET/CT in the initial staging of colorectal cancer.^{15,46} On the contrary, PET/CT may be recommended for patients with known metastatic colon cancer who are being considered for curative resection as the identification of otherwise unrecognized metastatic disease may alter the treatment plan. A meta-analysis of 18 studies, including more than 1000 patients with hepatic colorectal metastases showed that PET or PET/CT findings led to a change in management in 24% of patients.⁶⁰ PET-CT may also be useful in the evaluation of patients with equivocal findings (eg, retroperitoneal lymphadenopathy) on CT or MRI.⁵²

5. Colon cancer should typically be staged according to the American Joint Committee on Cancer, Tumor, Node, Metastasis (AJCC/TNM) system and should include an assessment of the completeness of surgical resection. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

The tumor depth, nodal metastasis, and distant metastasis have been shown to be predictors of prognosis in colon cancer. These characteristics are described by the American Joint Committee on Cancer TNM staging system and are included in Table 3. The current (8th) edition expanded the definition of metastatic disease to include the M1c category for peritoneal implants, clarified the definition of tumor deposits (N1c), and also highlighted the importance of lymphovascular and perineural invasion, microsatellite instability (MSI), tumor budding, and mutations in KRAS, NRAS, and BRAF in treatment considerations.⁶¹ As with previous editions, a positive lymph node is defined as one containing a ≥ 0.2 mm deposit of cancer cells. Although debate continues regarding the prognostic value of “isolated tumor cells” or clumps of tumor cells measuring < 0.2 mm in regional lymph nodes, these terms are not included in the AJCC/TNM staging system.^{62–64}

In addition to tumor-node-metastasis staging, the histologic grade of the tumor as well as the completeness of the resection should be assessed. Histologic grade, particularly poor cellular differentiation, has been shown to be a predictor of outcome and is an important consideration for some treatment recommendations.⁶⁵ The absence or presence of residual tumor after resection is designated by the terms indeterminate (ie, margin of excision cannot be assessed), negative (ie, margin uninvolved with invasive adenocarcinoma)

or positive (ie, invasive adenocarcinoma ≤ 1 mm from the excision margin) in accordance with the AJCC protocols for colorectal cancer pathology specimen processing.⁶⁶

SURGICAL TREATMENT OF THE PRIMARY

6. When neoadjuvant therapy is not included in the treatment plan, curative intent colectomy should be performed without unneeded delay. Grade of recommendation: strong recommendation based on low quality evidence, 1C

The impact of the time interval from colon cancer diagnosis to curative intent surgery on oncological outcome remains unclear. While a recent retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) and National Cancer Databases indicated that a delay in surgery of 3 to 6 weeks was associated with a decrease in overall survival, a Canadian population-based retrospective study and two recent single-center studies indicated that surgical delays of up to 12 weeks are not detrimental to disease-free or overall survival.^{67–70} While a specific interval to surgery cannot be recommended with the available data, untreated cancer progresses over time, and as such, surgery should be completed without unneeded delay. Meanwhile, patients undergoing neoadjuvant therapy have a treatment timeline determined by the specifics of their care plan.

7. At the time of surgery, a thorough exploration should be performed and the findings should be documented in the operative report. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.

The surgical exploration includes visual inspection and, when possible, during open surgery, palpation of the peritoneal cavity and the abdominal and pelvic organs to detect or rule out synchronous lesions, or more advanced malignant disease (eg, peritoneal metastasis or adjacent organ involvement). In the event that peritoneal metastases are incidentally discovered during exploration it is recommended that biopsies are obtained to confirm the diagnosis and that the extent and distribution of disease are determined and documented, ideally with use of the peritoneal cancer index.⁷¹ In general, and in the absence of obstruction or perforation, both colectomy and cytoreductive surgery should be deferred until multidisciplinary discussion of treatment is completed and informed consent is obtained from the patient.⁷²

The operative report should include a description of the relevant preoperative workup and findings on exploration, including the presence of synchronous metastases or gross involvement of mesenteric lymph nodes, tumor site, and adjacent organ involvement. The report should also describe treatment details including type of incision, severity of adhesions, occurrence and repair of unintended bowel injuries, extent of bowel and mesenteric resection, level of feeding vessel ligation, anastomotic

TABLE 3. The American Joint Committee on Cancer, Colorectal Cancer Staging System

<i>Definition of primary tumor (T)</i>	
T category	T criteria
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ, intramucosal adenocarcinoma (involvement of lamina propria no extension through the muscularis mucosae)
T1	Tumor invades submucosa
T2	Tumor invades muscularis propria
T3	Tumor invades through the muscularis propria into the pericolonic tissue
T4a	Tumor penetrates to the surface of the visceral peritoneum (serosa)
T4b	Tumor invades and/or is adherent to other organs or structures

<i>Regional lymph node staging (N)</i>	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	One to three regional lymph nodes are positive (tumor in lymph nodes measuring ≥ 0.2 mm), or any number of tumor deposits are present and all identifiable lymph nodes are negative
N1a	One regional lymph node is positive
N1b	Two to three regional lymph nodes are positive
N1c	No regional lymph nodes are positive, but there are tumor deposits in subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastases
N2a	Four or more regional lymph nodes are positive
N2b	Seven or more regional lymph nodes are positive

<i>Distant metastasis staging (M)</i>	
M0	No distant metastasis
M1a	Metastasis confined to one organ or site is identified without peritoneal metastasis
M1b	Metastasis confined to two or more organs or sites is identified without peritoneal metastasis
M1c	Metastasis to the peritoneal surface is identified alone or with other site or organ metastases

<i>Stage</i>	<i>T</i>	<i>N</i>	<i>M</i>
0	Tis	N0	M0
I	1-2	N0	M0
IIA	T3	N0	M0
IIB	T4a	N0	M0
IIC	T4b	N0	M0
IIIA	T1-T2	N1-N1c	M0
IIIB	T1	N2a	M0
	T3-T4a	N1-N1c	M0
	T2-T3	N2a	M0
IIIC	T1-2	N2b	M0
	T4a	N2a	M0
	T3-T4a	N2b	M0
IVA	T4b	N1-N2	M0
	Any T	Any N	M1a
IVB	Any T	Any N	M1b
IVC	Any T	Any N	M1c

AJCC = American Joint Committee on Cancer; RCT = randomized controlled trial

technique, en bloc resection of contiguously involved organs, and an intraoperative assessment of the completeness of resection including margin status. Synoptic operative reports have been shown to improve the documentation of key surgical factors and are currently being developed by the American College of Surgeons Commission on Cancer.^{73,74}

8. The extent of resection of the colon should correspond to the lymphovascular drainage of the colon cancer. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

The extent of a curative resection for colon cancer depends on the site of the primary lesion and its lymphovascular drainage. In the absence of synchronous pathology, a

colon resection for cancer should generally include proximal and distal longitudinal margins of 5 to 7 cm to ensure adequate removal of at risk pericolic lymph nodes.^{75,76} In addition, the mesentery to the tumor-bearing segment of bowel should be removed up to the origin of the named primary feeding vessel(s) to enable removal of the draining intermediate and central lymph nodes.^{77,78} For example, as long as there is no clinical lymphadenopathy outside of the standard field of resection, with a right-sided colon cancer, the ileocolic pedicle and right branch of the middle colic artery are divided at their origins. For a sigmoid colon cancer, the superior rectal artery and left colic artery are divided at their origins, and the inferior mesenteric vein is divided near the inferior edge of the pancreas. The resection should be performed with preservation of the integrity of the colonic mesentery.^{79,80} As the total number of lymph nodes evaluated at the time of resection has been associated with survival, the lymph node examination should be as complete as possible.^{81–84} It is recommended that at least 12 lymph nodes be evaluated to confidently assign an N0 stage, and the examination of fewer than 12 lymph nodes is a high-risk feature for stage II colon cancer.^{85,86} In the event that fewer than 12 lymph nodes are reported on the pathology report, the surgeon should request additional evaluation and processing and reporting of the specimen in accordance to the guidelines set forth by the College of American Pathologists.^{66,87}

Cancers of the transverse colon and splenic flexure deserve specific consideration regarding the extent of resection and what constitutes an appropriate lymphadenectomy. While a 2019 meta-analysis of patients with transverse colon cancer indicated that transverse colectomy and extended right or left colectomy resulted in comparable short- and long-term outcomes, a 2020 Italian national study concluded that, compared with patients undergoing extended resections, segmental resection patients had fewer postoperative complications, including anastomotic leak (2% vs 4%, $p < 0.05$) and improved three-year disease-free survival (86% vs 78% ($p < 0.05$)).^{88,89} In a 2021 NCDB study of stages I to III transverse colon cancer, unadjusted five-year survival was similar for extended and segmental resection (40.7% vs 41.3%, $p = 0.34$), but after adjusting for covariates, extended colectomy for transverse colon cancer was associated with lower survival (HR 1.07; 95% CI 1.04–1.10; $p < 0.001$).⁹⁰ With this inconsistency in the reported data, an individual determination of resection extent based upon careful inspection of the tumor and its feeding vessel(s) and consideration of the functional outcomes related to each resection type is recommended.

Cancers of the splenic flexure usually metastasize to lymph nodes along the left colic pedicle.^{91,92} However, positive lymph nodes have also been identified along the superior mesenteric artery and its tributaries, including the middle colic, right colic, and ileocolic arteries at a rate

of up to 9%.⁹³ Despite this observation, retrospective studies and a meta-analysis suggest segmental resections are a reasonable alternative to extended colectomy under these circumstances.^{90,94–96}

9. Routine extended lymphadenectomy is not recommended. Grade of recommendation: weak recommendation based on moderate-quality evidence, 2B.

Lymph node metastasis outside the standard field of resection (ie, at the level of the D3 lymph nodes) occurs in 3% to 11% of colon cancers and is more likely with advanced T-stage cancers.^{97–100} Central lymph node involvement in the absence of pericolic or intermediate lymph node involvement (“skip metastases”) occurs in 0% to 4% of cases.^{101,102} Extended lymphadenectomy, which may be termed “central vascular ligation,” or “D3 resection,” refers to lymph node retrieval proximal to the primary feeding vessel and the associated central (D2) lymph node basin. This dissection retrieves lymphatic tissue along the superior mesenteric artery and vein during right colon cancer resection and at the origin of the inferior mesenteric artery for sigmoid cancer colectomy. In contrast, the term “complete mesocolic excision” refers to the completeness of the mesocolic envelop within a colon cancer resection specimen, and does not designate a particular level of vascular ligation.¹⁰³

While extended lymphadenectomy has been shown to result in higher lymph node yields and potentially improved N-staging, it has also been associated with increased operative and postoperative complications.^{97,104–107} Recent observational studies and a meta-analysis suggest that extended lymphadenectomy is associated with decreased rates of cancer recurrence and improved recurrence-free survival.^{108–110} On the contrary, other studies, including a systematic review, have shown no survival benefit with extended lymphadenectomy.^{104,106,111,112} With the equipoise in the current literature, further studies are needed before a strong recommendation on routine extended lymphadenectomy may be offered. Rather, as central/D3 lymph node positivity is associated with decreased recurrence-free survival, selective dissection and retrieval, including harvesting of clinically positive or suspicious lymph nodes outside the standard field of resection, is recommended.¹¹³

10. For resectable colon cancers that adhere to or invade adjacent organs and are being treated with curative intent, complete and en bloc resection with negative margins is recommended. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

Local tumor control is achieved by complete resection of the tumor en bloc with contiguously involved structures.^{114–117} Adhesions between a colon cancer and surrounding organs should not be divided as they have been shown to harbor malignant cells in 34% to 84% of patients.^{114,118,119}

The importance of a margin-negative resection was underscored in three recent large series of patients with colon cancer in whom margin-positive patients experienced significantly worse outcomes in terms of disease progression and disease-free and overall survival.^{120–122} Available diagnostic modalities (eg, CT or MRI) can identify adjacent organ involvement before surgical exploration and facilitate operative planning and assembly of a multispecialty surgical team, as needed.¹²³ With appropriate experience, both laparoscopic and robotic approaches appear appropriate for en bloc resection.^{124–129}

11. Oophorectomy is typically advised for grossly abnormal ovaries or contiguous extension of colon cancer, but routine prophylactic oophorectomy is not recommended. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.

In patients with apparent direct colon cancer extension involving an ovary, en bloc oophorectomy should typically be performed as part of a curative-intent resection. In patients with suspected or known metastatic disease involving an ovary, oophorectomy has been associated with a survival benefit in retrospective series of selected patients.¹³⁰ In these situations, bilateral oophorectomy should typically be performed even if one ovary appears grossly normal.^{130–132} In patients with grossly normal-appearing ovaries, the data do not support routine prophylactic oophorectomy at the time of colorectal cancer resection.¹³³ However, prophylactic oophorectomy should be considered in women with colon cancer with an inherited risk for developing ovarian cancer and in postmenopausal women desiring risk reduction. In breast cancer susceptibility gene 1 or 2 (BRCA1 or BRCA2) carriers, oophorectomy has been associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer and a 77% reduction in all-cause mortality.¹³⁴

12. In patients with locally advanced colon cancer, neoadjuvant chemotherapy or radiotherapy can result in tumor regression and may facilitate margin-negative excision of locally advanced cancers. Grade of recommendation: weak recommendations based on moderate-quality evidence, 2B.

Neoadjuvant chemotherapy and/or radiotherapy may be considered to facilitate complete excision of locally advanced colon cancers.^{135–139} The current NCCN guidelines include a recommendation to consider neoadjuvant oxaliplatin-based chemotherapy for patients with “bulky nodal disease or clinical T4b” colon cancer.¹⁵ In a 2020 systematic review of six studies, neoadjuvant chemotherapy resulted in tumor volume reduction in two-thirds of patients and major pathological tumor regression in 4% to 37% of patients, improved three-year disease-free survival in responders compared with nonresponders (94% vs 63%, $p = 0.005$), and a 23% lower rate of death at three years in matched patients with

cT4b tumors who received neoadjuvant compared with adjuvant chemotherapy (HR 0.77, 95% CI 0.6–0.98; $p = 0.04$) but no benefit for cT3 or cT4a tumors.¹⁴⁰

The FOxTROT trial, a prospective study from the United Kingdom, randomized 1053 subjects with cT3-4N0-3M0 colon cancer to receive either oxaliplatin-based adjuvant chemotherapy (12 cycles) or neoadjuvant therapy (3 cycles) followed by surgery and adjuvant chemotherapy (9 cycles).¹³⁷ Provisional results, published in abstract form, indicated no differences between groups in postoperative morbidity or mortality. Patients treated with neoadjuvant chemotherapy had significant T and N stage downstaging ($p < 0.001$), a pathological complete response rate of 3.8%, and a trend toward less recurrent or persistent disease at two years (14.0% vs 17.5%).¹⁴¹ Publication of the full manuscript with longer follow-up may strengthen or change our recommendation.

The PRODIGE 22 trial, a French multicenter collaboration, included 104 patients with cT3-4 and/or N2 colon cancers randomized to curative resection followed by adjuvant chemotherapy (12 cycles) or neoadjuvant chemotherapy (four cycles) followed by surgery and then adjuvant chemotherapy (eight cycles).¹⁴² Subjects in the neoadjuvant arm were more likely to achieve tumor regression grades 1-2 (44% vs 8%, $p < 0.001$) and had a significantly increased rate of pTNM downstaging. However, there were no differences in three-year overall survival (90.3% vs 90.4%) or three-year disease-free survival (76.8% vs 69.2%) in the neoadjuvant and adjuvant-only arms, respectively. A limitation of PRODIGE 22 was clinical overstaging in one-third of patients in the adjuvant therapy (control) arm, indicating that overtreatment may have occurred in the neoadjuvant (experimental) arm of the study.

While both FOxTROT and PRODIGE 22 did not show a survival advantage with neoadjuvant chemotherapy, a 2018 retrospective analysis of the National Cancer Database (NCDB) found a three-year overall survival advantage (74% vs 66%, $p = 0.002$) among patients with cT4b colon cancers treated with neoadjuvant compared with adjuvant chemotherapy.¹⁴³ After propensity score matching, the improvement in overall survival among patients with clinical cT4b cancers was 23% higher in the neoadjuvant group (HR 0.77, 95% CI 0.60–0.98, $p = 0.004$). There were no survival advantages among the NCDB patients with cT3 or cT4a cancers related to the use of neoadjuvant therapy.

Neoadjuvant radiation therapy is not widely used; however, both a single-center study and a National Cancer Database study concluded that neoadjuvant radiation for cT4 disease may be associated with tumor downstaging, superior R0 resection rates, and improved overall survival.^{138,139} In these complex scenarios, multidisciplinary decision-making is recommended.

13. Synchronous colon cancers may be treated by two segmental resections or subtotal colectomy. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

The term synchronous colon cancer is used to describe situations in which a second primary colon cancer is diagnosed at the same time, or up to 12 months after, as detection of the index colon cancer.¹⁴⁴ Synchronous cancers have been reported to occur in 4% to 5% of patients and have been associated with decreased overall survival.^{34,145} Synchronous cancers in the same segment of the colon are removed with a segmental colectomy, whereas synchronous cancers in separate segments of the colon may be treated with an extended resection or two segmental resections.¹⁴⁶ Whereas extended resections do not incur increased surgical morbidity and have not been associated with a survival benefit, the functional outcomes associated with this approach may diminish the subsequent quality of life.^{34,147}

When colon cancer is associated with an underlying colonic disease (eg, chronic ulcerative colitis or hereditary nonpolyposis colorectal cancer syndrome), the extent of resection should consider the underlying disorder. These considerations are beyond the scope of this Clinical Practice Guideline and are discussed in other Clinical Practice Guidelines.^{7,148}

14. When expertise is available, a minimally invasive approach to elective colectomy for colon cancer is preferred. Grade of recommendation: strong recommendation based on high-quality evidence, 1A.

Minimally invasive surgical (MIS) approaches for colon cancer surgery include multiport, single-port, and hand-assisted laparoscopy and robotic techniques. Although certain lesions may not be amenable to a minimally invasive approach because of various factors (ie, large size or adjacent organ invasion), in most circumstances, MIS is preferred given appropriate expertise and experience. Most important, MIS procedures should achieve the same goals as open surgery; when this is not possible, conversion to open surgery is recommended. Several large multi-institutional randomized trials with experienced surgeons in the United States and internationally have demonstrated equivalent oncological outcomes with decreased length of hospital stay and other short-term outcome improvements with multiport laparoscopy compared with open surgical resection of localized colon cancer.^{149–153} Although transverse colon cancers were excluded from the sentinel trials that compared laparoscopic and open colectomy for colon cancer, more recent nonrandomized data and meta-analyses indicate oncological equivalence and improved short-term outcomes with a laparoscopic technique in this setting.^{154–157}

Observational studies and a meta-analysis of single-port laparoscopic surgery demonstrate equivalent surgical

and oncological results as multiport laparoscopy.^{158–161} In addition, two randomized controlled trials of 195 and 200 patients comparing single-port versus multiport laparoscopic surgery found no differences in operative times, number of harvested lymph nodes, lengths of resection margins or postoperative complications.^{162,163}

Randomized controlled trials of hand-assisted laparoscopic surgery (HALS) versus open or conventional laparoscopic right colectomy for cancer indicate similar short-term outcomes for the laparoscopic and HALS techniques, less pain and faster recovery with hand-assisted laparoscopy compared with open surgery, and no differences in the long-term oncological outcomes.^{164,165} A randomized controlled trial of robotic versus laparoscopic right colectomy for colon cancer indicated no differences in postoperative morbidity or short-term cancer-related outcomes but increased operative time and costs for the robotic group.¹⁶⁶ While numerous reports support HALS and robotic surgery for right colectomy, there remains insufficient evidence to allow meaningful recommendations for left-sided colon cancer resections using these techniques. However, as long as operations are performed according to the principals of colon cancer surgery, it is reasonable to conclude that left-sided colectomies are also suitable for a HALS or robotic approach.

15. For patients with a “malignant polyp,” either endoscopic excision or oncological resection may be appropriate depending largely on polyp histopathological features and completeness of excision. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

Patients with a malignant polyp, a T1 cancer arising in an adenomatous polyp,⁵⁵ may be adequately treated by endoscopic excision or may require oncological colon resection. Conventional colonoscopic polypectomy techniques, endoscopic mucosal resection, endoscopic submucosal dissection, or combined endoscopic and laparoscopic surgery techniques have all been used safely and successfully to avoid colectomy in patients with low-risk malignant colon polyps.^{167–171} An initial attempt at nonpiecemeal complete endoscopic excision is typically warranted in selected patients as this will be curative in >80% of patients.^{172–174} Polypectomy excision margin, depth of submucosal (SM) invasion of cancer cells, degree of cellular differentiation, lymphovascular and perineural invasion (LVI and PNI), and amount of tumor budding are the histopathological factors that require consideration when endoscopic excision or colectomy is being considered.

The definition of a negative polypectomy excision margin is a point of debate, with earlier reports indicating the need for a ≥ 2 mm margin.¹⁷⁵ A 2012 USA single-center review of 143 patients with a malignant polyp who underwent endoscopic excision and subsequent colectomy

found residual cancer at the polypectomy site or regional lymph nodes in 0%, 9%, 16% and 5%, 21% and 7% of patients with polypectomy excision margins of ≥ 1 mm, < 1 mm, or indeterminate.¹⁷² A 2013 analysis of the north of England NORCCAG (NORthern Colorectal Cancer Audit Group) database found malignant polyp excision margins of 0 and > 0 mm resulted in residual cancer at the polypectomy site or regional lymph nodes in 34% and 5% of patients, respectively.¹⁷³ In a 2018 Scottish national study, patients with complete polyp excision were subsequently found to have residual cancer at the polypectomy site or regional lymph nodes in 7% and 7%, respectively, whereas, in patients with incomplete polyp excision, residual cancer at the polypectomy site or regional lymph nodes occurred in 29% and 9%. This Scottish study also showed that a polyp excision margin of ≥ 1 mm did not reduce the risk of residual cancer after polypectomy when compared with a negative margin of ≥ 0 mm.¹⁷⁴

Submucosal invasion depth is an important prognostic factor for malignant polyps. This depth may be stratified as superficial, intermediate, or deep invasion (ie, SM 1, 2, or 3) or by the measured depth into the submucosa (eg, < 500 , 500–1000, or > 1000 μm).^{176,177} In a 2013 systematic review, SM 1, 2, and 3 invasion were associated with lymph node metastasis in 3.4%, 8.5%, and 22.6% of patients, respectively.¹⁷⁸ Additional studies, cited above, add further support to the poor prognostic value of SM3/ > 1000 μm invasion depth and may be used to support oncological resection when present. The Haggitt classification may also be used to stratify risk for lymph node metastasis or other adverse outcomes related to a malignant polyp. As Haggitt reported in 1985, when malignant invasion was limited to the head, neck, or stalk (ie, level 1, 2, or 3) of a pedunculated polyp, there were no lymph node metastases and only one of 101 patients (1%) died with colorectal cancer.¹⁷⁹ As a result, it is generally accepted that complete excision of a pedunculated malignant polyp with level 1-3 invasion is adequate, providing that no other adverse factors (eg, LVI, poor differentiation, etc). Alternatively, for patients with Haggitt level 4 invasion, defined as cancer cells in the submucosa at the base of a pedunculated or sessile polyp, seven of 28 (25%) of Haggitt patients were diagnosed with lymph node or systemic metastasis. Subsequent studies noted lymph node metastasis in as many as 13% of patients with “level 4” malignant polyps, which supported the idea that colectomy was required in these patients.^{180,181} However, we now know that SM depth and Haggitt level are only two of many variables that should be considered when a malignant polyp is categorized as low or high risk and when endoscopic excision or oncological resection is appropriate.

A 2013 systematic review and meta-analysis of patients with pT1 colorectal cancer who underwent oncological resection revealed that 11% overall had lymph node involvement and that LVI, submucosal invasion depth

≥ 1 mm, poorly differentiated cancer, and tumor budding were associated with lymph node metastasis in 22%, 12%, 24%, and 21% of cases, respectively.¹⁷⁸

A low-risk malignant pedunculated or sessile polyp may be defined as one with well- or moderately differentiated cancer, no LVI or PNI, no or low tumor budding, a negative resection margin, and < 1 mm submucosal invasion depth. Endoscopic endoscopic excision is generally considered definitive treatment for these malignant polyps as the risk of residual disease in the colon wall or cancerous lymph nodes is negligible. Alternatively, when a sessile or pedunculated malignant polyp contains a poorly differentiated cancer, a positive or indeterminate margin, or > 1 mm depth of submucosal invasion, segmental oncological resection is generally warranted, as the risk of recurrence in the colon wall or regional lymph node involvement is unacceptably high.^{171,172,174,182–184}

COLON CANCER-RELATED EMERGENCIES

Approximately 20% of patients with colon tumors present with surgical emergencies such as bleeding, perforation, or obstruction.¹⁸⁵ The goals of treatment in these situations are to: 1) avert the immediate negative impacts of the complication (eg, death or sepsis), 2) achieve the best possible tumor control, and 3) ensure timely recovery to permit initiation of appropriate systemic treatment, as needed.

16. For patients with obstructing left-sided colon cancer and curable disease, the choice of endoscopic stent decompression, diverting colostomy with interval colectomy, or initial treatment with oncological segmental colectomy should be individualized based upon patient factors and local expertise of the institution. grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

A 2020 systematic review and meta-analysis of 27 studies and nearly 4000 patients, the majority of whom had an obstructing left-sided colon cancer, indicated that initial stenting in curative cases resulted in more frequent use of a primary anastomosis, decreased morbidity and 30-day mortality, and no significant differences in three- or five- disease-free years or overall survival.¹⁸⁶ A 2017 meta-analysis of eight randomized controlled trials comparing stenting as a bridge to surgery with emergency resection limited to left-sided cancers demonstrated a 60-day mortality of 9.6% and 9.9% ($p > 0.05$), 60-day morbidity of 34% and 51% ($p = 0.02$), a temporary ostomy rate of 34% and 51% ($p < 0.001$), and primary anastomosis rates of 70% and 54% ($p = 0.04$), respectively.¹⁸⁷ Further, in this 2017 analysis, the emergency resection group required a permanent ostomy more frequently (35% vs 22%). Notwithstanding these data, initial treatment of these patients with oncological segmental resection may be appropriate for select

patients in whom the risks of a nondiverted anastomosis are low or when a temporary diverting ileostomy is acceptable to both the patient and surgeon.

While successful stent placement has been reported in 77% to 81% of patients, stenting carries a perforation rate of 2% to 9%. Patients who develop a perforation related to stenting are at increased risk of locoregional cancer recurrence.^{188–191}

A diverting colostomy may be an alternative to stenting for patients with an obstructing left-side colon cancer. In recent Dutch national population-based cohort studies of matched patients with obstructing left-side colon cancer who underwent initial diverting ostomy or initial endoscopic stent decompression, the patients who were initially treated with a diverting stoma were more likely to undergo subsequent laparoscopic resection of the obstructed colon segment (57% vs 9%, $p < 0.001$), had more primary anastomoses (88% vs 41%, $p < 0.001$), reduced 90-day mortality (1.7% vs 7.2%, $p = 0.03$), a significant improvement in three-year overall survival (79% vs 73% (95% CI 0.20–0.65)) and fewer permanent stomas (22% vs 42%, $p < 0.0010$).^{192,193}

Ultimately, the condition of the patient, surgeon experience, available endoscopic expertise, and informed decision-making by the patient should all be considered to select the optimal treatment option for each patient who presents with an obstructing left-side colon cancer.

17. For patients with obstructing right or transverse colon cancer and curable disease, initial colectomy or initial endoscopic stent decompression with subsequent interval colectomy may be performed. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.

For patients with obstructing cancers of the right or transverse colon, oncological segmental resection with ileocolic anastomosis can be safely performed in most cases.¹⁹⁴ Creation of a primary anastomosis in this setting depends on the patient's general condition at the time of resection and the absence of other factors that indicate the need for a defunctioning or end stoma.

While most studies evaluating stenting as a bridge to surgery (SBTS) have focused on left-sided obstructions, recent retrospective studies demonstrate that selected patients with right-sided lesions can be safely and effectively stented. Successful right-sided stent placement has been reported in 87% to 96% of cases.^{195,196} In a Japanese national database study of 1500 matched patients who underwent emergent right colectomy or SBTS, the SBTS group utilized laparoscopy more often (50% vs 25%, $p < 0.001$), had fewer stomas created (1.7% vs 5.1%, $p < 0.001$), and had decreased length of stay (13 vs 15 days, $p < 0.001$).¹⁹⁷ A 2020 systematic review and meta-analysis of emergent colectomy or SBTS for obstructing right-sided colon cancer demonstrated similar five-year disease-free and overall survival between the treatment groups.¹⁹⁸

18. In the setting of perforation or impending perforation of the colon, resection following established oncological principles with a low threshold for performing a staged procedure is recommended when feasible. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.

Several retrospective studies have compared outcomes between perforated and nonperforated colon cancers.^{191,199,200} In general, patients with a perforation are less likely to have a primary anastomosis and have increased rates of postoperative morbidity and mortality. Additionally, patients with perforated cancers have significantly lower five-year disease-free survival and overall survival¹⁹⁹ and higher rates of metachronous peritoneal carcinomatosis.²⁰¹ Patients with free perforations have worse overall survival than patients with contained perforations.²⁰⁰ In cases with perforation of uninvolved colon proximal to an obstructing tumor, resection of the tumor following usual oncological principles is recommended. In addition, the perforated segment should be addressed by repair or resection with or without diversion according to standard surgery principles. An anastomosis (with or without proximal diversion) may be considered, as an alternative to end colostomy creation, in selected patients with minimal contamination, healthy tissue quality, and clinical stability. Alternatively, with contained or free-perforation complicated by abscess or peritonitis, oncological resection with end ostomy should be considered. The use of a self-expanding metal stent is contraindicated in the setting of perforated colon cancer.²⁰²

19. Acute lower GI bleeding from a newly diagnosed colon cancer should be initially managed with nonsurgical approaches when feasible. Grade of recommendation: strong recommendation based on low-quality evidence, 1C.

Anemia secondary to chronic blood loss is common in patients with colon cancer, and this does not typically alter the timing and approach to surgery. However, acute massive lower GI bleeding from a colon cancer is a potentially life-threatening complication. In cases of GI bleeding without a known source, resuscitation of the patient followed by attempts to localize the site of bleeding are indicated. Options for preoperative localization include radionuclide imaging, CT angiography, conventional angiography, and colonoscopy. In studies of GI bleeding from various pathologies, CT angiography has proven superior to radionuclide imaging (sensitivity 85% compared with 20% to 60%, respectively).^{203–206} Conventional angiography detects bleeding in 40% to 90% of patients and can be combined with angiographic embolization, which results in cessation of bleeding in 70% to 90% of patients.²⁰⁷ Urgent colonoscopy has a yield of 20% to 40% in patients with a lower GI bleed and, like angiography, has the advantage of being both diagnostic and therapeutic.^{207,208} When

nonsurgical methods fail to control bleeding from a colon cancer, surgical intervention is generally required. Under these circumstances, an oncological resection is recommended, when it can be safely performed, in keeping with established surgical principles.

MANAGEMENT OF LOCOREGIONAL RECURRENCE

20. Treatment options for patients with local or local-regional recurrence of colon cancer should be considered in a multidisciplinary setting. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

The true incidences of local and local-regional recurrence (LRR) for colon cancer are difficult to determine as series often combine these outcomes with patients with distant disease and report on colon cancer patients together with rectal cancer patients. The most recent, robust studies report LRR in 4-7% of patients, half of whom have concurrent systemic disease. The median interval between initial resection and LRR is 18 to 24 months.²⁰⁹⁻²¹¹ Risk factors for LRR include higher T and N stages, left-sided tumors, omission of chemotherapy, a positive surgical margin at the index operation, and lymphovascular invasion.^{185,209,210} Asymptomatic LRRs may be heralded by an elevated CEA level or discovered on surveillance colonoscopy or computed tomography, while others present with symptoms of bleeding, pain, or obstruction.²¹² LRRs may occur at the anastomosis, but more often occur outside the lumen and may adhere to adjacent organs.²¹³ In patients with LRR, CT, MRI, and FDG PET/CT are employed to determine disease extent and resectability.^{46,55} When LRR occurs in isolation, or in the presence of resectable metastases, salvage surgery can be attempted with reasonable short and long-term outcomes. These outcomes vary based on disease burden and the ability to achieve an R0 resection, but are predictably better for patients with isolated anastomotic recurrences compared with patients requiring multivisceral resection or who have oligometastatic disease.^{211,212,214}

A 2016 systematic review evaluated overall survival following resection of locally recurrent colon cancer. The review included data on 550 patients from eight retrospective cohort studies and one population-based registry.²¹² More than half of patients had a multivisceral resection. Rerecurrence occurred in 41 of 188 patients (22%). The median overall survival for patients who underwent resection ranged from 14 to 42 months, the pooled overall five-year survival was 52%, and patients who had an R0 resection had the best outcomes. The postoperative morbidity rate ranged from 21% to 68%, but most complications were considered minor. Factors predictive of prolonged survival after resection for LRR included having an R0 resection, early stage of initial disease,

no associated distant disease, and a single site of recurrence. Chemotherapy and radiotherapy were commonly employed in the included series, but the timing and specifics of therapy were variable.²¹² One study included 15 selected patients with locally recurrent colon cancer adherent to other structures and used neoadjuvant chemoradiation to achieve an 87% R0 resection rate and a 100% three-year survival rate.²¹³ While another study identified preoperative chemotherapy or radiation as a predictor of having an R0 resection.²¹⁵ Intraoperative radiation therapy has also shown improved outcomes with low morbidity in small series with recurrent and locally advanced disease.²¹²

MANAGEMENT OF STAGE IV COLON CANCER

A. Resectable or Potentially Resectable Stage IV Colon Cancer

21. The treatment of patients with resectable stage IV colon cancer should be individualized and based on a comprehensive multidisciplinary discussion. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

When considering treatment for stage IV patients, it is important to distinguish between clearly resectable metastatic disease and disease that is potentially convertible to resectable if tumors regress after chemotherapy. Conversion to resectability has been described with standard chemotherapy regimens usually with the addition of bevacizumab or cetuximab.^{216,217} When metastatic disease is considered resectable or potentially resectable, resection of the primary tumor should be considered as, in general, medically fit patients with resectable hepatic and/or pulmonary metastases will benefit from curative resection of the metastases.^{218,219} The utilization of a multidisciplinary conference has been shown to increase the use of metastasectomy and increase survival in patients with stage IV colorectal cancer.^{220,221}

22. Patients with initially resectable colon cancer liver metastasis can be treated with neoadjuvant chemotherapy followed by surgical resection or up-front surgery. Grade of recommendation: weak recommendation based on moderate-quality evidence, 2B.

The role of systemic chemotherapy in the setting of resectable liver metastases was addressed in EORTC 40983 in which patients with up to four resectable liver metastases were randomly assigned to either liver surgery alone (ie, no neoadjuvant or adjuvant chemotherapy) or to six cycles of neoadjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), then metastasectomy, and then six cycles of adjuvant FOLFOX.²²² Complications of liver resection were increased in the chemotherapy arm (25% vs 16% ($p = 0.04$)). At three-year follow-up, there was a 7% better progression-free survival in the perioperative chemotherapy group compared with the surgery-alone group

(35% vs 28%, $p = 0.04$). At a median follow-up of 8.5 years (interquartile range 7.6–9.5), five-year overall survival did not significantly differ among treatment groups (51% for those who received perioperative chemotherapy and 48% among those who underwent surgery alone).²²³ Due to the improvement in progression-free survival in the perioperative chemotherapy group, the EORTC investigators recommended this treatment paradigm. In the current NCCN guidelines, up-front surgery or neoadjuvant chemotherapy then surgery followed by adjuvant therapy are recommended approaches for patients with resectable synchronous or metachronous colon cancer liver metastasis.¹⁵

23. Patients with initially unresectable colon cancer liver metastasis should be considered for neoadjuvant chemotherapy to attempt to convert to resectability. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

A 2017 systematic review and meta-analysis of 11 studies demonstrated that oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)-based neoadjuvant chemotherapy combined with bevacizumab effectively converted 39% (27–53%) of patients with initially unresectable colon cancer liver metastasis to resectable, and of these “converted” patients, an R0 resection was achieved in 28% (18–41%).²²⁴ In the FIRE-3 trial, reported in 2018, patients with metastatic colorectal liver tumors were assessed before and after treatment with irinotecan-based chemotherapy (FOLFIRI) and bevacizumab or cetuximab (for KRAS wild-type cancers), and resectability increased from 22% to 53% ($p < 0.001$).²²⁵ A 2020 systematic review of 20 trials has shown that neoadjuvant use of FOLFOX or FOLFIRI or a combination of 5-FU, oxaliplatin, and irinotecan (FOLFIRINOX) plus bevacizumab or cetuximab (for KRAS wild-type cancers) will result in an overall response rate of 55% to 85%, a conversion to resectability in 10% to 61%, and an RO-resection rate of as high as 54%.²²⁶

24. Hepatic artery infusion of chemotherapy combined with systemic chemotherapy or immunotherapy may increase resectability of colon cancer liver metastasis, but should only be performed in centers with the appropriate expertise. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

In the single-arm OPTILIV trial, of patients with KRAS wild-type unresectable colorectal liver metastases, hepatic artery infusion (HAI) of irinotecan, oxaliplatin, and 5-FU, plus systemic cetuximab, enabled R0 or R1 metastasectomy in 19 of 64 patients (29.7%). These 19 responders had a median overall survival, of 35 (33–38) months.²²⁷ Two reports of a single phase 2 trial indicated that HAI of floxuridine, in combination with systemic oxaliplatin or irinotecan-based chemotherapy, with or without bevacizumab produced response rates of 76% and 73% and conversion to resectability in 47% and 52%.^{228,229} In one of these reports, the patients who

ultimately underwent resection had a three-year overall survival (OS) rate of 80%, which compared favorably with the 30% OS in patients who did not undergo resection.²²⁸ In the other report, the five-year OS of resected patients was 63.3% (95% CI 43.6–77.7%) and 12.5% for unresected patients (95% CI 3.5–27.3%) ($p \leq 0.001$).²²⁹ Notably, treatment-related toxicity was high in these studies, as 77% of patients in the OPTILIV trial and 41% of the phase 2 trial patients whose regimen included bevacizumab had grade 3 or 4 toxicity (eg, neutropenia, abdominal pain, and diarrhea). Further, in the OPTILIV trial, major complications (eg, hepatic artery thrombosis or arteritis) led to interruption of HAI delivery in nearly one-half of the study patients.

25. In patients with colon cancer and resectable liver metastasis, a single “combined” operation is generally recommended for relatively low complexity operations and sequential or “staged” operations are generally recommended for higher complexity cases. Grade of recommendation: weak recommendation based on moderate-quality evidence, 2B.

Patients with resectable stage IV disease limited to the liver should undergo resection of both the primary tumor as well as the metastatic foci and the sequence of resection should be individualized for each patient, but it is important that the procedure be done in a center with the expertise to handle both the colon surgery and the liver resection. In 2003, a retrospective study by Martin and colleagues showed that combined resections ($n=134$) were less complex (ie, more right colectomies and smaller and fewer liver lesion) than the staged resections ($n = 106$) and had lower overall morbidity (49% vs 67%, $p < 0.003$) and decreased total hospital stay (10 vs 18 days, $p < 0.001$).²³⁰ A subsequent multicenter retrospective study by Reddy et al that included 475 staged and 135 combined colorectal and liver resections showed that the addition of a colorectal resection to a minor hepatectomy resulted in no increase in severe morbidity (12.5% vs 14.1%) but that the addition of a colorectal resection to a major hepatectomy resulted in an increase in severe morbidity compared with major liver resection alone (36.1% vs 15.1%, $p < 0.05$), and that major hepatectomy was an independent predictor of severe morbidity (HR 3.4, $p = 0.008$).²³¹ A 2015 NSQIP study provided evidence in favor of combined operations for relatively low-complexity operations and staged operations for more complex cases.²³² In this study, estimated cumulative postoperative morbidity ranged from as low as 25% for a low-risk colectomy (eg, right colectomy) combined with a low-risk hepatic resection (eg, left hepatectomy) to as high as 39% for a high-risk colectomy (eg, total abdominal colectomy) combined with high-risk hepatic resection (eg, right hepatectomy). Meanwhile, in another more recent retrospective study that included 145 simultaneous and 53 staged colorectal and liver resections, severe complications (Calvien-Dindo grade III-IV) occurred in 15% and 19% of patients ($p = 0.51$),

respectively. In a subgroup analysis, patients who underwent simultaneous or staged major hepatectomy, 63% and 56% experienced a postoperative complication of any grade ($p = 0.70$), including 23% and 18% that were severe (p value not provided), suggesting that simultaneous resections may be safe even for more complex cases when performed at centers with appropriate expertise.²³³

26. In patients with resectable colon cancer lung metastasis, resection of the lung lesions should be considered as it may prolong survival. Grade of recommendation: weak recommendation based on moderate-quality evidence, 2B.

A 2019 retrospective study of 345 patients with colorectal cancer lung metastasis who underwent anatomical or non-anatomical lung resection demonstrated a median overall survival of 101 months, with the best outcomes in patients with KRAS wild-type cancers and those who underwent anatomical resection.²³⁴ A Japanese national retrospective study of 553 patients who underwent colorectal cancer lung metastasectomy reported five-year recurrence-free survival in 49% and 36% and five-year overall survival in 80% and 68% of patients who underwent segmentectomy ($n = 98$) or wedge resection ($n = 455$), respectively.²³⁵ In a Spanish national registry study (2008–2010), in which a variety of excision types were performed in 522 patients, median disease-free and disease-specific survival were 28 and 55 months, respectively, with the best outcomes in patients who had a major resection with lymphadenectomy.²¹⁹ A 2015, Japanese, single-center retrospective study of 94 patients reported a five-year overall survival of 45%, a significantly better rate of five-year survival for colon compared with rectal metastasis (62% vs 24%, $p = 0.03$) but cancer recurrence (local or distant) in 69% of patients at a median of 11.5 (0–50) months.²³⁶ In the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) Cohort Study, which randomly assigned patients with resectable colorectal cancer lung metastases to metastasectomy or no metastasectomy, median overall survival was 3.5 (3.1–6.6) years and 3.8 (3.5–4.6) years, respectively, supporting the position that nonsurgical treatment of these patients should also be considered.²³⁷ Stereotactic body radiation therapy (SBRT) may also be considered in these cases but appears to be less efficacious than resection in terms of both progression-free and overall survival when compared with metastasectomy.²³⁸

27. In patients with resectable colorectal cancer peritoneal metastases, cytoreductive surgery with or without intraperitoneal chemotherapy should be considered in a multidisciplinary setting with appropriate expertise. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

In patients with stage IV disease, as many as 25% will have metastatic disease that is limited to the peritoneum.^{239,240}

In these patients, initial treatment options include systemic chemotherapy and/or resection of the peritoneal cancer with or without intraperitoneal chemotherapy. Systemic therapy using modern chemotherapeutic agents and targeted biologic therapies has improved outcomes of patients with colorectal cancer-associated carcinomatosis, who now have a median survival in the range of 16 to 24 months.²⁴¹ Unfortunately, the five-year overall survival with systemic oxaliplatin-based chemotherapy alone is less than 5%, and there is minimal benefit from adding bevacizumab.^{242,243}

The surgical approach to colorectal cancer associated peritoneal metastases generally includes the combination of cytoreductive surgery in conjunction with hyperthermic intraperitoneal mitomycin-C or oxaliplatin with or without hyperthermia.^{71,244} With this approach, in more than 500 patients treated in France, five-year overall and disease-free survival were 27% and 10%, respectively, with survival inversely proportional to the extent of peritoneal disease as described by the Peritoneal Cancer Index (PCI).⁷¹ Other studies have reported median survival in the range of 22 to 63 months, and five-year overall survival in 19% to 51% of patients with this approach.^{245–250} In the first randomized trial of cytoreductive surgery and intraperitoneal chemotherapy versus systemic oxaliplatin-based chemotherapy in this setting, two- and five-year overall survival rates were 54% and 38% ($p = 0.04$) and 33% and 4% ($p = 0.02$), respectively.²⁴⁹ The completeness of surgical cytoreduction is also directly related to overall survival after hyperthermic intraperitoneal chemotherapy (HIPEC).²⁵¹ In 2021, the results of the PRODIGE-7 multicenter randomized, controlled trial that compared cytoreduction alone ($n = 132$) versus cytoreduction and HIPEC ($n = 133$) raised doubts about the value of HIPEC given the higher rates of severe adverse events in the HIPEC arm but no associated overall survival benefit (41–42 months in both arms).²⁵² The 2020 Chicago Consensus on the management of peritoneal metastasis of colorectal cancer acknowledged the PRODIGE-7 results (unpublished at the time) and recommended preoperative systemic chemotherapy (\pm immunotherapy in MSI-H cancers) for high-risk cases, initial cytoreductive surgery for low-risk cases with or without the use of intraperitoneal chemotherapy.²⁵³

B. Unresectable Stage IV Colon Cancer

Patients who present with widely metastatic colon cancer are usually not candidates for surgical cure. Meanwhile, other patients may not be candidates for radical, curative resection due to systemic comorbidities. In these situations, a multidisciplinary management approach to potential palliation is recommended. In patients with incurable metastatic colon cancer who have an asymptomatic colon primary, the value of colectomy is debatable. The goals of palliation should be relief of symptoms caused by the

cancer and maintenance of quality of life. Palliative therapy often includes systemic chemotherapy. Palliative surgical interventions for obstruction of the GI tract or intractable bleeding caused by colon cancer include resection, endoluminal stent therapy, ablative procedures, internal bypass, or creation of a diverting stoma. The individual patient's overall life expectancy should also be considered when making palliative intervention decisions.

28. In patients with incurable stage IV colon cancer and an asymptomatic primary colon cancer, systemic chemotherapy is recommended as the initial treatment. Grade of Recommendation: Strong recommendation based on moderate quality evidence, 1B.

For patients with incurable stage IV colon cancer and an asymptomatic primary colon tumor, there are conflicting reports on the value of primary tumor resection. A strong argument in favor of an initial nonoperative approach may be based on the prospective multicenter phase NSABP C-10 trial, which evaluated patients with colon cancer, an intact primary colon tumor, and unresectable metastases who were treated with up-front FOLFOX chemotherapy and bevacizumab.²⁵⁴ In this trial, with 21-month follow-up, 14% of patients experienced major morbidity related to the primary colon tumor and 12% required operation, most often for colon obstruction. In addition, a SEER database (1998–2013) analysis of 4692 patients with stage IV colorectal cancer (74% colon and 26% rectal) unplanned operations were also required in 12% of patients.²⁵⁵ In this SEER analysis, the probability of requiring unplanned surgery between six and 12 months, 12 and 24 months, and >24 months were 8.1%, 6.7%, and 5.3%, respectively, and female gender, left-side colon tumors, and younger age were risk factors for unplanned operation. Further, a 2017 multivariate analysis of the National Cancer Database that included adjustments for potential cofounder effects, indicated no survival benefit with resection of the asymptomatic primary tumor compared with chemotherapy alone.²⁵⁶ Finally, in 2021, the results of the JCOG1007- iPACS trial, in which 165 patients stage IV colorectal cancer and an asymptomatic primary tumor were randomly assigned to either chemotherapy alone (84 patients) or primary tumor resection (PTR) plus chemotherapy (81 patients) were reported. With a median follow-up of 22 months, the median overall survival was 25.9 months (95% CI 19.9–31.5) in the PTR plus chemotherapy arm and 26.7 (95% CI 21.9–32.5) in the chemotherapy-alone arm (HR 1.10; 95% CI 0.76–1.59; $p = 0.69$).²⁵⁷

On the contrary, the evidence in favor of initial operative treatment is relatively weak and comes from a 2016 single-center adjusted retrospective analysis, a 2016 observational study of Canadian provincial data, and a 2019 meta-analysis that each reached the conclusion that palliative resection of the primary tumor was associated with improved survival compared with chemotherapy alone and

without significant increase in morbidity.^{258–260} Additional evidence in favor of initial resection of the primary tumor may be obtained from a 2018 analysis of eight randomized trials included in the ARCAD database, which showed improved progression-free (9.7 vs 7.9 months, HR 1.31 (1.19–1.44) and overall survival (22.2 vs 16.4 months, HR 1.60 (1.43–1.78)) in patients who underwent resection of the primary colon tumor.²⁶¹ In this ARCAD analysis, the majority of patients had colon cancer, all received oxaliplatin or irinotecan-based systemic chemotherapy, most were also treated with targeted, antibody therapies, but it was not clear precisely how often the colon primary was actually asymptomatic. This same limitation was present in a 2018 analysis of the NCDB (2004–2012) that showed improved overall survival (22 vs 13 months) in the primary tumor resection group. The most recently published data in favor of initial surgery in this setting comes from a 2020 Korean prospective multicenter trial of 48 patients who were randomized to upfront primary resection versus chemotherapy alone and revealed a two-year cancer-specific survival rate of 72% in the resection group and 47% in the chemotherapy group ($p = 0.05$) with a clinically relevant but statistically insignificant improvement in overall survival (69% vs 45%, $p = 0.06$), respectively. The primary tumor-related complication rate was 23% in the chemotherapy group and postoperative complications developed in five patients (19%; 4% major) after colon resection.²⁶² However, while results this study are noteworthy it is also notable that the trial was stopped early due to insufficient enrollment and that four of the 48 enrolled patients were lost to follow-up.

Thus, with the currently available evidence, although an argument may be made in favor of initial surgical treatment for these patients, a stronger case may be made for initial chemotherapy, evaluation of response, estimation of prognosis, and repeat discussion in the multidisciplinary setting. The results of ongoing prospective clinical trials (CAIRO4 and GRECCAR 8) are awaited as they may provide additional data to guide decision-making in these patients.

29. In patients with an obstructing colon cancer and incurable metastatic disease, or in other scenarios where palliation is preferred over an attempt at cure, endoscopic stent placement or diverting colostomy is preferable to colectomy when life expectancy is less than one year. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B

In the palliative setting, endoscopic stent decompression of an obstructing colon cancer is preferable to initial colectomy as it has been shown to result in decreased mortality, ostomy use, and interval to initiation of chemotherapy with no difference in survival.^{202,263–266} Compared with patients without peritoneal metastases, patients with peritoneal metastases are less likely to have successful colonic

stent placement and experience a higher complication rate.^{267–269} Endoluminal stenting in the palliative setting, has a median duration of patency of 106 (68–288) days and one-, six-, and 12-month stent patency rates of 69%, 54%, and 50%, respectively.^{270,271} When tumor ingrowth results in recurrent obstruction, placing a stent through the obstructed stent has proven safe and effective in the majority of patients.^{272,273} An observational cohort study assessed the outcomes of 345 patients who required urgent or emergent hospitalization for obstructing colorectal cancer who were treated with an ostomy or a stent without plans for further resection.²⁷⁴ Patients who were treated with a stent were significantly less likely to experience a prolonged length of stay and were more likely to be discharged to their usual residence. Readmission rates were similar for the two groups, as were reoperations at 90 days but reoperation at one year was more often needed in the stent group. With regard to bevacizumab in patients who are treated by an endoluminal stent, a meta-analysis published in 2014 showed a higher rate of colon perforations in patients whose treatment included bevacizumab (12.5%) compared with chemotherapy alone (7%), but more recent retrospective studies have demonstrated no increase in stent-related perforation among bevacizumab treated patients.^{269,275,276}

CHEMOTHERAPY, IMMUNOTHERAPY, AND MOLECULAR ADJUNCTS

30. In stage II colon cancer patients with microsatellite stable/mismatch repair proficient cancer, obstruction, perforation, <12 lymph nodes in the resection specimen, poor differentiation, lymphovascular invasion, perineural invasion, or high-level tumor budding, adjuvant chemotherapy may offer a survival benefit. Grade of recommendation: weak recommendation based on moderate-quality evidence, 2B

Stage II colon cancer patients are a heterogeneous group with an expected five-year overall survival that ranges from as high as 90% for a patient with a T3, well-differentiated cancer to as low as 74% for a patient with a poorly differentiated, T4b cancer.⁷⁰ High-risk stage II colon cancers include those that present with obstruction or perforation, or have <12 lymph nodes in the resection specimen, a close or positive resection margin, T4b tumor depth, poor differentiation, lymphovascular invasion, perineural invasion, or high-level tumor budding, or are microsatellite stable/mismatch repair proficient on histopathology.^{55,277–285} There is conflicting data regarding the role of adjuvant chemotherapy in stage II colon cancer. Most of the randomized trials studying adjuvant therapy for colon cancer enrolled both stage II and stage III patients and some demonstrated a small difference corresponding to a potential absolute improvement in

overall survival of approximately 2% to 3% with 5-FU/LV and 3% to 4% with FOLFOX in the stage II patients.^{286–289} However, the proportion of patients with stage II cancers was approximately 20% to 25% in these trials, limiting the ability to draw definitive conclusions. Although initial subgroup analysis of the MOSAIC trial suggested a benefit of adding oxaliplatin to adjuvant chemotherapy for high-risk stage II patients, a more recent analysis of these data showed no benefit to oxaliplatin in the treatment of stage II disease, regardless of whether the patients were classified as low or high risk.^{290,291} A 2016, pooled analysis of five prospective trials, in which fluorouracil-based adjuvant chemotherapy was compared with oxaliplatin-based adjuvant chemotherapy in patients with stage II colon cancer, indicated that the addition of oxaliplatin resulted in an improvement in five-year disease-free recurrence (10.3% vs 15.3%, $p < 0.05$) but no difference in deaths at five years (9.4% vs 10.2%, $p > 0.05$).²⁹² Conversely, in another recent analysis of more than 150,000 stage II colon cancer patients included in the National Cancer Database (NCDB), the use of adjuvant chemotherapy was associated with improved survival irrespective of pathological risk factors.²⁹³ In this NCDB study, after covariate adjustment, patients with low or high-risk stage II colon cancer, treated without or with adjuvant fluorouracil or oxaliplatin-based chemotherapy, had a median survival of 8.8 and 13.2 years ($p < 0.001$) and 6.9 and 11.0 years ($p < 0.001$), respectively. Notwithstanding this NCDB data, with its methodology limitations related to its retrospective design, most data suggest that there is minimal to no benefit to adjuvant treatment in patients with “low-risk” stage II colon cancer. Stage II patients with one or more high-risk features have a risk of recurrence which approaches stage IIIa colon cancer and are routinely considered for adjuvant chemotherapy.^{277,279,282} Multigene assays and measurement of circulating tumor DNA (ctDNA) are emerging technologies that may also play a role in adjuvant therapy decisions in patients with stage II colon cancer (see Recommendation #34).

31. In patients with stage III colon cancer, adjuvant chemotherapy is generally recommended. Grade of recommendation: strong recommendation based on high-quality evidence: 1A.

In patients with stage III colon cancer, with MSI-high or MSI-low tumors, large multi-institutional US and international randomized clinical trials have demonstrated a survival benefit with adjuvant oxaliplatin-based chemotherapy.^{292,294–296} Oral capecitabine (Xeloda) is a safe and effective alternative to infusional 5-FU in this setting and, in combination with oxaliplatin (CAPOX), has outcomes similar to other established regimens (FOLFOX).^{295,297} Since 2004, a 6-month regimen of adjuvant chemotherapy has been the standard recommendation,^{286,290} however, the duration of adjuvant chemotherapy has recently been reassessed in part due to the toxicity (eg, neuropathy) associated with oxaliplatin use.²⁹⁸ In 2018, the

International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration reported no difference in outcomes for patients with T1-3N1 colon cancer who received three or six months of oxaliplatin-based adjuvant chemotherapy (three-year disease-free survival was 83% in both groups). However, in patients with T4 and/or N2 cancer, disease free survival was superior with six months of treatment.²⁹⁹ Therefore, duration of adjuvant chemotherapy should be decided based on patient characteristics, tumor stage, and an understanding of chemotherapy-related toxicity using a shared decision approach. Current evidence does not support the use of irinotecan-based chemotherapy.³⁰⁰⁻³⁰³ The addition of bevacizumab or certuzumab to FOLFOX for adjuvant therapy for stage III colon cancer is also not recommended as randomized trials have shown these agents increase the risk of severe adverse events without offering a survival advantage.^{304,305}

32. In patients with stage IV mismatch repair deficient (dMMR) or microsatellite high (MSI-H) colon cancer, immunotherapy targeting programmed cell death-ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1) should be considered. Grade of recommendation: strong recommendation based on high-quality evidence, 1A.

In 2020, the KEYNOTE-177 trial, in which 307 patients with dMMR/MSI-H stage IV colorectal cancer were randomized to first-line chemotherapy or pembrolizumab (anti PD-1), demonstrated improved progression-free survival (median 16.5 versus 8.2 months; $p = 0.0002$) in the pembrolizumab trial arm.³⁰⁶ In the CheckMate 142 trial, second line treatment (after cancer progression during treatment with FOLFOX or FOLFIRI or intolerance to these drugs) of 74 patients with dMMR/MSI-H stage IV colorectal cancer resulted in an objective response in 23 of 74 patients (31%) of whom eight (11%) had responses lasting 12 months.³⁰⁷ The KEYNOTE-164 trial involved a study population similar to the CheckMate 142 trial (ie, cancer progression on standard chemotherapy \pm anti-VEGF or anti-EGFR), and showed that pembrolizumab resulted in a response to treatment in 32% of patients and a 12-month progression-free survival of 41%.³⁰⁸ Atezolizumab, a monoclonal antibody to the programmed cell death-ligand 1 (PD-L1), is currently being studied in the ATOMIC trial in which patients with stage III dMMR colon cancer are randomized to adjuvant oxaliplatin-based chemotherapy with or without Atezolizumab. Meanwhile, therapies targeting PD-1 and PDL-1 are ineffective for the treatment of microsatellite stable/MMR proficient colorectal cancers.³⁰⁹

33. In general, adjuvant chemotherapy should be started within 8 weeks of colon resection. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

US National Cancer Database analyses of patients with stage III colon cancer from 2016 and 2018 demonstrated

maximal overall survival benefit of when adjuvant chemotherapy was started within six to eight weeks of resection, but adjuvant therapy remained beneficial even when started as long as 24 weeks after resection.^{310,311} A 2015 national study from the Netherlands also indicated that overall survival was decreased when adjuvant chemotherapy was started greater than eight weeks after resection of stage III colon cancer.³¹²

34. The use of multigene assays, CDX2 expression analysis, and circulating tumor DNA (ctDNA) may be used to complement multidisciplinary decision-making for patients with stage II or III colon cancer. Grade of recommendation: strong recommendation based on moderate-quality evidence, 1B.

Oncotype DX is an assay that quantifies the expression of five reference genes and seven recurrence risk genes as a prognostic classifier of low, intermediate, or high probability of colon cancer recurrence.³¹³ Oncotype DX used on tumor samples for patients with stage II colon cancer who were enrolled in the Cancer and Leukemia Group B (CALGB) 9581 study demonstrated that the recurrence score (RS, derived from a mathematical function combining the expression values of selected cancer-related genes) ranged from two to 78 (median 31.4), and that an increase in the RS by 25 was significantly associated with cancer recurrence (HR 1.52 (95% CI 1.09–2.12; $p = 0.013$)).³¹⁴ In a similar analysis of tumor samples from patients with stages II and II colon cancer enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 study, continuous RS predicted cancer recurrence and that cancer recurrences were increased in the high RS group compared with the low RS group of patients (HR 2.11 (95% CI 1.54–2.88, $p < 0.001$)) and that higher RS was associated with decreased disease-free and overall survival and increased benefit to oxaliplatinbased adjuvant chemotherapy.³¹⁵ In another study, in which a 13-gene assay, that used an analysis similar to Oncotype-DX, was used in stage II patient tumor samples from the Quick and Simple and Reliable (QUASAR) study, cancer recurrence at three years was reported in 12%, 18%, and 22% of patients in the low, intermediate, and high RS groups (HR 1.94, $p < 0.001$) but this information was not predictive of adjuvant chemotherapy benefit.³¹⁶ ColoPrint is a multigene assay that quantifies the expression of 18 genes into low or high probability of cancer recurrence. In a study of 206 patients with stage I-III colon cancer whose tumors were evaluated with ColoPrint, the five-year recurrence-free survival rates for low and high-probability groups were 88% (CI 81–94%) and 67% (CI 55–79%), respectively.³¹⁷ ColDx is an additional multigene assay that utilizes 634 probes-based and helps identify stage II colon cancer patients at high risk for recurrence.³¹⁸ In one study of stage II patients, those identified by ColDx as having a high risk of recurrence had a decreased recurrence-free survival when compared with low risk patients (HR 2.13 CI 1.3–3.5, $p < 0.01$).³¹⁹ CDX2

is a transcription factor that has recently been shown to be important in identifying high risk stage II colon cancer patients who may benefit from adjuvant chemotherapy. In stage II colon cancer, patients with CDX2-negative tumors had significantly lower five-year disease-free survival than patients with CDX2-positive tumors HR 3.44 CI 1.60–7.38; $p = 0.002$. The rate of five-year disease-free survival was higher in patients with CDX2-negative tumors who were treated with adjuvant chemotherapy versus those who were not (91% vs 56%, $p = 0.006$).³²⁰

Circulating tumor DNA (ctDNA) is fragments of cancer DNA that have entered the bloodstream and may be used as a marker for residual or recurrent disease. The presence of ctDNA may be used for both risk-assessment and to identify patients with resected colon cancer who may be at higher risk of recurrence.³²¹ In one study of 178 patients with stage II colon cancer, 14 (7.9%) had ctDNA detected postoperatively and 11 (79%) were diagnosed with cancer recurrence at a median follow-up of 27 months. In comparison, of 164 patients in whom ctDNA was not detected, only 16 (9.8%) recurred ($p < 0.001$).³²² Additionally, ctDNA may be helpful in surveillance after resection or chemotherapy to detect recurrences more rapidly than with standard surveillance.^{321,323–325} Studies have shown a correlation between a decrease in ctDNA during systemic therapy in metastatic colon cancer with tumor response.^{326–328} Thus, ctDNA is being studied in an effort to determine if it will be a useful marker for benefit from adjuvant treatment. In a prospective observation study of stage II patients, detection of ctDNA immediately after completion of adjuvant chemotherapy was associated with lower recurrence-free survival (HR 11, CI 1.8–68, $p = 0.001$).³²² In a similar study of stage III patients, patients with detectable ctDNA after completion of adjuvant treatment had a three-year recurrence-free survival of 30% vs 77% if ctDNA was not detectable (HR 6.8; CI 11–157, $p < 0.001$).³²⁵ An additional study reported a 17-fold higher risk of recurrence if ctDNA remained detectable after completion of adjuvant chemotherapy (HR 17.5 CI 5.4–56.5, $p < 0.001$).³²¹ These studies provide early support for the use of ctDNA to inform the use of adjuvant chemotherapy; however, they had limited sample size and a variety of different ctDNA assay platforms were used. Ongoing trials will address whether ctDNA will be a useful marker of survival, recurrence, and adjuvant therapy effectiveness (NCT04068103, COBRA; NCT04120701, CIRCULATE; ACTRN12615000381583, DYNAMIC-II). Notwithstanding these thought-provoking data on multigene assays, the current NCCN colon cancer guidelines state these tests “can further inform the risk of cancer recurrence over other risk factors,” but that there is insufficient data to recommend their use to estimate recurrence or determine adjuvant treatment.¹⁵ The European Society for Medical Oncology (ESMO) guidelines are similar to NCCN in that the routine use of these tests is

“not warranted” but that their use “might be considered in complementing clinicopathological information on intermediate risk stage II (colon cancer) scenarios.”⁴⁶

REFERENCES

1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin*. 2020;70:145–164.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70:7–30.
3. White A, Joseph D, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. *Cancer*. 2017;123(suppl 24):5014–5036.
4. Carmichael JC, Keller DS, Baldini G, et al. Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and Society of American Gastrointestinal and Endoscopic Surgeons. *Dis Colon Rectum*. 2017;60:761–784.
5. Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. *Dis Colon Rectum*. 2018;61:14–20.
6. Herzig D, Hardiman K, Weiser M, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of inherited polyposis syndromes. *Dis Colon Rectum*. 2017;60:881–894.
7. Herzig DO, Buie WD, Weiser MR, et al. Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome. *Dis Colon Rectum*. 2017;60:137–143.
8. Migaly J, Bafford AC, Francone TD, et al; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the use of bowel preparation in elective colon and rectal surgery. *Dis Colon Rectum*. 2019;62:3–8.
9. Steele SR, Chang GJ, Hendren S, et al; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. *Dis Colon Rectum*. 2015;58:713–725.
10. Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of colon cancer. *Dis Colon Rectum*. 2017;60:999–1017.
11. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. *Chest*. 2006;129:174–181.
12. Giglia MD, Chu DI. Familial colorectal cancer: understanding the alphabet soup. *Clin Colon Rectal Surg*. 2016;29:185–195.
13. Lu KH, Wood ME, Daniels M, et al; American Society of Clinical Oncology. American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers. *J Clin Oncol*. 2014;32:833–840.
14. Stoffel EM, Koeppel E, Everett J, et al. Germline genetic features of young individuals with colorectal cancer. *Gastroenterology*. 2018;154:897–905.e1.
15. *National Comprehensive Cancer Network. Colon Cancer (Version 2.2021)*.

16. Moreno CC, Mittal PK, Sullivan PS, et al. Colorectal cancer initial diagnosis: screening colonoscopy, diagnostic colonoscopy, or emergent surgery, and tumor stage and size at initial presentation. *Clin Colorectal Cancer*. 2016;15:67–73.
17. Leijssen LGJ, Dinaux AM, Kunitake H, Bordeianou LG, Berger DL. Detrimental impact of symptom-detected colorectal cancer. *Surg Endosc*. 2020;34:569–579.
18. Brenner H, Jansen L, Ulrich A, Chang-Claude J, Hoffmeister M. Survival of patients with symptom- and screening-detected colorectal cancer. *Oncotarget*. 2016;7:44695–44704.
19. Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. *Br J Cancer*. 2015;112:580–593.
20. Eliassen M, GrønkJær M, Skov-Ettrup LS, et al. Preoperative alcohol consumption and postoperative complications: a systematic review and meta-analysis. *Ann Surg*. 2013;258:930–942.
21. Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. *Int J Cancer*. 2008;122:155–164.
22. GrønkJær M, Eliassen M, Skov-Ettrup LS, et al. Preoperative smoking status and postoperative complications: a systematic review and meta-analysis. *Ann Surg*. 2014;259:52–71.
23. Bos ACRK, Kortbeek D, van Erning FN, et al. Postoperative mortality in elderly patients with colorectal cancer: the impact of age, time-trends and competing risks of dying. *Eur J Surg Oncol*. 2019;45:1575–1583.
24. Cheung WY, Renfro LA, Kerr D, et al. Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the adjuvant colon cancer endpoints database. *J Clin Oncol*. 2016;34:1182–1189.
25. Bruns ER, van den Heuvel B, Buskens CJ, et al. The effects of physical prehabilitation in elderly patients undergoing colorectal surgery: a systematic review. *Colorectal Dis*. 2016;18:O267–O277.
26. Trépanier M, Minnella EM, Paradis T, et al. Improved disease-free survival after prehabilitation for colorectal cancer surgery. *Ann Surg*. 2019;270:493–501.
27. Thirunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V. Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. *JAMA Surg*. 2015;150:747–755.
28. Becerra AZ, Probst CP, Tejani MA, et al. Evaluating the prognostic role of elevated preoperative carcinoembryonic antigen levels in colon cancer patients: results from the national cancer database. *Ann Surg Oncol*. 2016;23:1554–1561.
29. Amri R, Bordeianou LG, Sylla P, Berger DL. Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. *J Surg Oncol*. 2013;108:14–18.
30. Huang SH, Tsai WS, You JF, et al. Preoperative carcinoembryonic antigen as a poor prognostic factor in stage I-III colorectal cancer after curative-intent resection: a propensity score matching analysis. *Ann Surg Oncol*. 2019;26:1685–1694.
31. Kim CG, Ahn JB, Jung M, et al. Preoperative serum carcinoembryonic antigen level as a prognostic factor for recurrence and survival after curative resection followed by adjuvant chemotherapy in stage III colon cancer. *Ann Surg Oncol*. 2017;24:227–235.
32. Margalit O, Mamtani R, Yang YX, et al. Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. *Eur J Cancer*. 2018;94:1–5.
33. Colloca GA, Venturino A, Guarneri D. Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis. *Int J Colorectal Dis*. 2019;34:657–666.
34. Thiels CA, Naik ND, Bergquist JR, et al. Survival following synchronous colon cancer resection. *J Surg Oncol*. 2016;114:80–85.
35. Bick BL, Vemulapalli KC, Rex DK. Regional center for complex colonoscopy: yield of neoplasia in patients with prior incomplete colonoscopy. *Gastrointest Endosc*. 2016;83:1239–1244.
36. Kim MS, Park YJ. Detection and treatment of synchronous lesions in colorectal cancer: the clinical implication of perioperative colonoscopy. *World J Gastroenterol*. 2007;13:4108–4111.
37. Flor N, Ceretti AP, Luigiano C, et al. Performance of CT colonography in diagnosis of synchronous colonic lesions in patients with occlusive colorectal cancer. *AJR Am J Roentgenol*. 2020;214:348–354.
38. Horvat N, Raj A, Ward JM, Smith JJ, Markowitz AJ, Gollub MJ. Clinical value of ct colonography versus preoperative colonoscopy in the surgical management of occlusive colorectal cancer. *AJR Am J Roentgenol*. 2018;210:333–340.
39. Huisman JF, Leicher LW, de Boer E, et al. Consequences of CT colonography in stenosing colorectal cancer. *Int J Colorectal Dis*. 2017;32:367–373.
40. Kim WS, Lee HS, Lee JM, et al. Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography for the detection of proximal synchronous lesions in patients with obstructive colorectal cancer. *J Gastroenterol Hepatol*. 2017;32:401–408.
41. Cerdán Santacruz C, Esteban López-Jamar JM, Sánchez López E, Cerdán Miguel J. Contribution of intraoperative colonoscopy in a colorectal surgery unit. *Scand J Gastroenterol*. 2017;52:1292–1297.
42. Simmerman EL, King RS, Ham PB III, Hooks VH III. Feasibility and safety of intraoperative colonoscopy after segmental colectomy and primary anastomosis. *Am Surg*. 2018;84:1175–1179.
43. Milsom JW, Shukla P. Should intraoperative colonoscopy play a role in the surveillance for colorectal cancer? *Dis Colon Rectum*. 2011;54:504–506.
44. Kahi CJ, Boland CR, Dominitz JA, et al; United States Multi-Society Task Force on Colorectal Cancer. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. *Gastroenterology*. 2016;150:758–768.e11.
45. Ridolfi TJ, Valente MA, Church JM. Achieving a complete colonic evaluation in patients with incomplete colonoscopy is worth the effort. *Dis Colon Rectum*. 2014;57:383–387.
46. Argilés G, Tabernero J, Labianca R, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;31:1291–1305.
47. Hogan J, O'Rourke C, Duff G, et al. Preoperative staging CT thorax in patients with colorectal cancer: its clinical importance. *Dis Colon Rectum*. 2014;57:1260–1266.
48. Kim HY, Lee SJ, Lee G, et al. Should preoperative chest CT be recommended to all colon cancer patients? *Ann Surg*. 2014;259:323–328.
49. Benson AB III, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2017;15:370–398.
50. Lazzaron AR, Vieira MV, Damin DC. Should preoperative chest computed tomography be performed in all patients with colorectal cancer? *Colorectal Dis*. 2015;17:O184–O190.

51. Engelmann BE, Loft A, Kjær A, et al. Positron emission tomography/computed tomography for optimized colon cancer staging and follow up. *Scand J Gastroenterol.* 2014;49:191–201.
52. Fowler KJ, Kaur H, Cash BD, et al; Expert Panel on Gastrointestinal Imaging. ACR appropriateness criteria(R) pretreatment staging of colorectal cancer. *J Am Coll Radiol.* 2017;14:S234–S244.
53. Gore RM, Pickhardt PJ, Mortele KJ, et al. Management of incidental liver lesions on CT: a white paper of the acr incidental findings committee. *J Am Coll Radiol.* 2017;14:1429–1437.
54. Gore RM, Thakrar KH, Wenzke DR, Newmark GM, Mehta UK, Berlin JW. That liver lesion on MDCT in the oncology patient: is it important? *Cancer Imaging.* 2012;12:373–384.
55. Ayez N, van der Stok EP, de Wilt H, et al. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. *BMC Cancer.* 2015;15:180.
56. Tsili AC, Alexiou G, Naka C, Argyropoulou MI. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis. *Acta Radiol.* 2021;62:302–312.
57. Elekonawo FMK, Starremans B, Laurens ST, et al. Can [18F] F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? *Abdom Radiol (NY).* 2020;45:301–306.
58. Pfannenbergh C, Königsrainer I, Aschoff P, et al. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol.* 2009;16:1295–1303.
59. Parnaby CN, Bailey W, Balasingam A, et al. Pulmonary staging in colorectal cancer: a review. *Colorectal Dis.* 2012;14:660–670.
60. Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. *Eur J Nucl Med Mol Imaging.* 2015;42:152–163.
61. Amin MB, Edge S, Greene F, et al; American Joint Committee on Cancer. *AJCC Cancer Staging Manual*; 8th ed. Chicago, IL: Springer; 2017.
62. Mescoli C, Albertoni L, Pucciarelli S, et al. Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer. *J Clin Oncol.* 2012;30:965–971.
63. Sloothaak DA, Sahami S, van der Zaag-Loonen HJ, et al. The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. *Eur J Surg Oncol.* 2014;40:263–269.
64. Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. *J Clin Oncol.* 2012;30:60–70.
65. Konishi T, Shimada Y, Lee LH, et al. Poorly differentiated clusters predict colon cancer recurrence: an in-depth comparative analysis of invasive-front prognostic markers. *Am J Surg Pathol.* 2018;42:705–714.
66. Washington MK, Berlin J, Branton P, et al; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. *Arch Pathol Lab Med.* 2009;133:1539–1551.
67. Lino-Silva LS, Guzmán-López JC, Zepeda-Najar C, Salcedo-Hernández RA, Meneses-García A. Overall survival of patients with colon cancer and a prolonged time to surgery. *J Surg Oncol.* 2019;119:503–509.
68. Wanis KN, Patel SVB, Brackstone M. Do moderate surgical treatment delays influence survival in colon cancer? *Dis Colon Rectum.* 2017;60:1241–1249.
69. Flemming JA, Nanji S, Wei X, Webber C, Groome P, Booth CM. Association between the time to surgery and survival among patients with colon cancer: A population-based study. *Eur J Surg Oncol.* 2017;43:1447–1455.
70. Kucejko RJ, Holleran TJ, Stein DE, Poggio JL. How soon should patients with colon cancer undergo definitive resection? *Dis Colon Rectum.* 2020;63:172–182.
71. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol.* 2010;28:63–68.
72. Brind'Amour A, Dubé P, Tremblay JF, et al. Canadian guidelines on the management of colorectal peritoneal metastases. *Curr Oncol.* 2020;27:e621–e631.
73. American College of Surgeons - options for synoptic operative reporting for commission on cancer (coc) standards 5.3-5.6.2021 at <https://www.facs.org/quality-programs/cancer/news/options--021921.>)
74. Maniar RL, Hochman DJ, Wirtzfeld DA, et al. Documentation of quality of care data for colon cancer surgery: comparison of synoptic and dictated operative reports. *Ann Surg Oncol.* 2014;21:3592–3597.
75. Hashiguchi Y, Hase K, Ueno H, Mochizuki H, Shinto E, Yamamoto J. Optimal margins and lymphadenectomy in colonic cancer surgery. *Br J Surg.* 2011;98:1171–1178.
76. Rørvig S, Schlesinger N, Mårtensson NL, Engel S, Engel U, Holck S. Is the longitudinal margin of carcinoma-bearing colon resections a neglected parameter? *Clin Colorectal Cancer.* 2014;13:68–72.
77. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome. *Colorectal Dis.* 2009;11:354–64; discussion 364.
78. Watanabe T, Itabashi M, Shimada Y, et al; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. *Int J Clin Oncol.* 2012;17:1–29.
79. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. *J Clin Oncol.* 2010;28:272–278.
80. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. *Lancet Oncol.* 2008;9:857–865.
81. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. *J Natl Cancer Inst.* 2007;99:433–441.
82. Del Paggio JC, Peng Y, Wei X, et al. Population-based study to re-evaluate optimal lymph node yield in colonic cancer. *Br J Surg.* 2017;104:1087–1096.

83. Nissan A, Protic M, Bilchik AJ, Howard RS, Peoples GE, Stojadinovic A. United States military cancer institute clinical trials group (USMCI GI-01) randomized controlled trial comparing targeted nodal assessment and ultrastaging with standard pathological evaluation for colon cancer. *Ann Surg.* 2012;256:412–427.
84. Tsai HL, Huang CW, Yeh YS, et al. Factors affecting number of lymph nodes harvested and the impact of examining a minimum of 12 lymph nodes in stage I–III colorectal cancer patients: a retrospective single institution cohort study of 1167 consecutive patients. *BMC Surg.* 2016;16:17.
85. Wells KO, Hawkins AT, Krishnamurthy DM, et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest. *Dis Colon Rectum.* 2017;60:15–21.
86. Jessup JMGR, Asare EA, et al. *Colon and Rectum.* 8th ed. New York, New York: Springer; 2017.
87. Lisovsky M, Schutz SN, Drage MG, Liu X, Suriawinata AA, Srivastava A. Number of lymph nodes in primary nodal basin and a “second look” protocol as quality indicators for optimal nodal staging of colon cancer. *Arch Pathol Lab Med.* 2017;141:125–130.
88. Milone M, Degiuli M, Allaix ME, et al. Mid-transverse colon cancer and extended versus transverse colectomy: Results of the Italian society of surgical oncology colorectal cancer network (SICO CCN) multicenter collaborative study. *Eur J Surg Oncol.* 2020;46:1683–1688.
89. Milone M, Manigrasso M, Elmore U, et al. Short- and long-term outcomes after transverse versus extended colectomy for transverse colon cancer. A systematic review and meta-analysis. *Int J Colorectal Dis.* 2019;34:201–207.
90. Crippa J, Grass F, Achilli P, et al. Surgical approach to transverse colon cancer: analysis of current practice and oncological outcomes using the national cancer database. *Dis Colon Rectum.* 2021;64:284–292.
91. Nakagoe T, Sawai T, Tsuji T, et al. Surgical treatment and subsequent outcome of patients with carcinoma of the splenic flexure. *Surg Today.* 2001;31:204–209.
92. Vasey CE, Rajaratnam S, O’Grady G, Hulme-Moir M. Lymphatic Drainage of the Splenic Flexure Defined by Intraoperative Scintigraphic Mapping. *Dis Colon Rectum.* 2018;61:441–446.
93. Manceau G, Mori A, Bardier A, et al. Lymph node metastases in splenic flexure colon cancer: is subtotal colectomy warranted? *J Surg Oncol.* 2018;118:1027–1033.
94. de’Angelis N, Hain E, Disabato M, et al. Laparoscopic extended right colectomy versus laparoscopic left colectomy for carcinoma of the splenic flexure: a matched case-control study. *Int J Colorectal Dis.* 2016;31:623–630.
95. Degiuli M, Reddavid R, Ricceri F, et al; and Members of the Italian Society of Surgical Oncology Colorectal Cancer Network (SICO-CCN) Collaborative Group [A listing of all authors appears at the end of the article]. Segmental colonic resection is a safe and effective treatment option for colon cancer of the splenic flexure: a nationwide retrospective study of the Italian society of surgical oncology-colorectal cancer network collaborative group. *Dis Colon Rectum.* 2020;63:1372–1382.
96. Martínez-Pérez A, Brunetti F, Vitali GC, Abdalla S, Ris F, de’Angelis N. Surgical treatment of colon cancer of the splenic flexure: a systematic review and meta-analysis. *Surg Laparosc Endosc Percutan Tech.* 2017;27:318–327.
97. Bertelsen CA, Kirkegaard-Klitbo A, Nielsen M, Leotta SM, Daisuke F, Gögenur I. Pattern of colon cancer lymph node metastases in patients undergoing central mesocolic lymph node excision: a systematic review. *Dis Colon Rectum.* 2016;59:1209–1221.
98. Hida J, Okuno K, Yasutomi M, et al. Optimal ligation level of the primary feeding artery and bowel resection margin in colon cancer surgery: the influence of the site of the primary feeding artery. *Dis Colon Rectum.* 2005;48:2232–2237.
99. Kanemitsu Y, Komori K, Kimura K, Kato T. D3 lymph node dissection in right hemicolectomy with a no-touch isolation technique in patients with colon cancer. *Dis Colon Rectum.* 2013;56:815–824.
100. Kawada H, Kurita N, Nakamura F, et al. Incorporation of apical lymph node status into the seventh edition of the TNM classification improves prediction of prognosis in stage III colonic cancer. *Br J Surg.* 2014;101:1143–1152.
101. Merrie AE, Phillips LV, Yun K, McCall JL. Skip metastases in colon cancer: assessment by lymph node mapping using molecular detection. *Surgery.* 2001;129:684–691.
102. Tan KY, Kawamura YJ, Mizokami K, et al. Distribution of the first metastatic lymph node in colon cancer and its clinical significance. *Colorectal Dis.* 2010;12:44–47.
103. Paquette IM, Madoff RD, Sigurdson ER, Chang GJ. Impact of proximal vascular ligation on survival of patients with colon cancer. *Ann Surg Oncol.* 2018;25:38–45.
104. Olofsson F, Buchwald P, Elmståhl S, Syk I. No benefit of extended mesenteric resection with central vascular ligation in right-sided colon cancer. *Colorectal Dis.* 2016;18:773–778.
105. Xu L, Su X, He Z, et al; RELARC Study Group. Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial. *Lancet Oncol.* 2021;22:391–401.
106. Gouvas N, Agalianos C, Papaparaska K, Perrakis A, Hohenberger W, Xynos E. Surgery along the embryological planes for colon cancer: a systematic review of complete mesocolic excision. *Int J Colorectal Dis.* 2016;31:1577–1594.
107. Karachun A, Panaiotti L, Chernikovskiy I, et al. Short-term outcomes of a multicentre randomized clinical trial comparing D2 versus D3 lymph node dissection for colonic cancer (COLD trial). *Br J Surg.* 2020;107:499–508.
108. Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Five-year outcome after complete mesocolic excision for right-sided colon cancer: a population-based cohort study. *Lancet Oncol.* 2019;20:1556–1565.
109. Gao Z, Wang C, Cui Y, et al. Efficacy and safety of complete mesocolic excision in patients with colon cancer: three-year results from a prospective, nonrandomized, double-blind, controlled trial. *Ann Surg.* 2020;271:519–526.
110. Numata M, Sawazaki S, Aoyama T, et al. D3 lymph node dissection reduces recurrence after primary resection for elderly patients with colon cancer. *Int J Colorectal Dis.* 2019;34:621–628.
111. Killeen S, Mannion M, Devaney A, Winter DC. Complete mesocolic resection and extended lymphadenectomy for colon cancer: a systematic review. *Colorectal Dis.* 2014;16:577–594.

112. Olofsson F, Buchwald P, Elmståhl S, Syk I. High tie or not in resection for cancer in the sigmoid colon? *Scand J Surg*. 2019;108:227–232.
113. Shinto E, Hida JI, Kobayashi H, et al. Prominent information of jN3 positive in stage III colorectal cancer removed by D3 dissection: retrospective analysis of 6866 patients from a multi-institutional database in Japan. *Dis Colon Rectum*. 2018;61:447–453.
114. Gezen C, Kement M, Altuntas YE, et al. Results after multivisceral resections of locally advanced colorectal cancers: an analysis on clinical and pathological t4 tumors. *World J Surg Oncol*. 2012;10:39.
115. Izbicki JR, Hosch SB, Knoefel WT, Passlick B, Bloechle C, Broelsch CE. Extended resections are beneficial for patients with locally advanced colorectal cancer. *Dis Colon Rectum*. 1995;38:1251–1256.
116. Lee JM, Chung T, Kim KM, et al. Significance of radial margin in patients undergoing complete mesocolic excision for colon cancer. *Dis Colon Rectum*. 2020;63:488–496.
117. Rosander E, Nordenvall C, Sjövall A, Hjern F, Holm T. Management and outcome after multivisceral resections in patients with locally advanced primary colon cancer. *Dis Colon Rectum*. 2018;61:454–460.
118. Eveno C, Lefevre JH, Svrcek M, et al. Oncologic results after multivisceral resection of clinical T4 tumors. *Surgery*. 2014;156:669–675.
119. Lehnert T, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. *Ann Surg*. 2002;235:217–225.
120. Amri R, Bordeianou LG, Sylla P, Berger DL. Association of radial margin positivity with colon cancer. *JAMA Surg*. 2015;150:890–898.
121. Goffredo P, Zhou P, Ginader T, et al. Positive circumferential resection margins following locally advanced colon cancer surgery: risk factors and survival impact. *J Surg Oncol*. 2020;121:538–546.
122. Khan MA, Hakeem AR, Scott N, Saunders RN. Significance of R1 resection margin in colon cancer resections in the modern era. *Colorectal Dis*. 2015;17:943–953.
123. Govindarajan A, Fraser N, Cranford V, et al. Predictors of multivisceral resection in patients with locally advanced colorectal cancer. *Ann Surg Oncol*. 2008;15:1923–1930.
124. Crolla RMPH, Tersteeg JJC, van der Schelling GP, Wijsman JH, Schreinemakers MJ. Robot-assisted laparoscopic resection of clinical T4b tumours of distal sigmoid and rectum: initial results. *Surg Endosc*. 2018;32:4571–4578.
125. deAngelis N, Vitali GC, Brunetti F, et al. Laparoscopic vs open surgery for T4 colon cancer: a propensity score analysis. *Int J Colorectal Dis*. 2016;31:1785–1797.
126. Elnahas A, Sunil S, Jackson TD, Okrainec A, Quereshy FA. Laparoscopic versus open surgery for T4 colon cancer: evaluation of margin status. *Surg Endosc*. 2016;30:1491–1496.
127. Liu ZH, Wang N, Wang FQ, Dong Q, Ding J. Oncological outcomes of laparoscopic versus open surgery in pT4 colon cancers: a systematic review and meta-analysis. *Int J Surg*. 2018;56:221–233.
128. Park JH, Park HC, Park SC, et al; SEoul COlorectal research Group (SECOG). Laparoscopic approach for left-sided T4 colon cancer is a safe and feasible procedure, compared to open surgery. *Surg Endosc*. 2019;33:2843–2849.
129. Yang X, Zhong ME, Xiao Y, et al. Laparoscopic vs open resection of pT4 colon cancer: a propensity score analysis of 94 patients. *Colorectal Dis*. 2018;20:O316–O325.
130. Lee SJ, Lee J, Lim HY, et al. Survival benefit from ovarian metastectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. *Cancer Chemother Pharmacol*. 2010;66:229–235.
131. Garrett CR, George B, Viswanathan C, et al. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. *Clin Colorectal Cancer*. 2012;11:191–194.
132. Huang PP, Weber TK, Mendoza C, Rodriguez-Bigas MA, Petrelli NJ. Long-term survival in patients with ovarian metastases from colorectal carcinoma. *Ann Surg Oncol*. 1998;5:695–698.
133. Young-Fadok TM, Wolff BG, Nivatvongs S, Metzger PP, Ilstrup DM. Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized, prospective trial. *Dis Colon Rectum*. 1998;41:277–283.
134. Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. *J Clin Oncol*. 2014;32:1547–1553.
135. Arredondo J, Baixela J, Pastor C, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. *Clin Transl Oncol*. 2017;19:379–385.
136. de Gooyer JM, Versteegen MG, 't Lam-Boer J, et al. Neoadjuvant chemotherapy for locally advanced t4 colon cancer: a nationwide propensity-score matched cohort analysis. *Dig Surg*. 2020;37:292–301.
137. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. *Lancet Oncol*. 2012;13:1152–1160.
138. Hawkins AT, Ford MM, Geiger TM, et al. Neoadjuvant radiation for clinical T4 colon cancer: a potential improvement to overall survival. *Surgery*. 2019;165:469–475.
139. Krishnamurthy DM, Hawkins AT, Wells KO, et al. Neoadjuvant radiation therapy in locally advanced colon cancer: a cohort analysis. *J Gastrointest Surg*. 2018;22:906–912.
140. Arredondo J, Pastor E, Simó V, et al. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. *Tech Coloproctol*. 2020;24:1001–1015.
141. Seymour MT, Morton D. International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. *J Clin Oncol*. 2019;15(suppl):3504–3504.
142. Karoui M, Rullier A, Piessen G, et al; for PRODIGE 22 investigators/collaborators. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). *Ann Surg*. 2020;271:637–645.
143. Dehal A, Graff-Baker AN, Vuong B, et al. Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. *J Gastrointest Surg*. 2018;22:242–249.
144. Mekenkamp LJ, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. *Br J Cancer*. 2010;103:159–164.

145. Bos ACRK, Matthijsen RA, van Erning FN, van Oijen MGH, Rutten HJT, Lemmens VEPP. Treatment and outcome of synchronous colorectal carcinomas: a nationwide study. *Ann Surg Oncol.* 2018;25:414–421.
146. Holubar SD, Wolff BG, Poola VP, Soop M. Multiple synchronous colonic anastomoses: are they safe? *Colorectal Dis.* 2010;12:135–140.
147. You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs extended colectomy: measurable differences in morbidity, function, and quality of life. *Dis Colon Rectum.* 2008;51:1036–1043.
148. Ross H, Steele SR, Varma M, et al; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum.* 2014;57:5–22.
149. Nelson H, Sargent DJ, Wieand HS, et al; Clinical outcomes of surgical therapy study group. a comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med.* 2004;350:2050–2059.
150. Buunen M, Veldkamp R, Hop WC, et al; Colon Cancer Laparoscopic or Open Resection Study Group. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. *Lancet Oncol.* 2009;10:44–52.
151. Deijen CL, Vasmel JE, de Lange-de Klerk ESM, et al; COLOR (Colon cancer Laparoscopic or Open Resection) Study Group. Ten-year outcomes of a randomised trial of laparoscopic versus open surgery for colon cancer. *Surg Endosc.* 2017;31:2607–2615.
152. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. *Br J Surg.* 2013;100:75–82.
153. Lacy AM, García-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. *Lancet.* 2002;359:2224–2229.
154. Mistrangelo M, Allaix ME, Cassoni P, Giraud G, Arolfo S, Morino M. Laparoscopic versus open resection for transverse colon cancer. *Surg Endosc.* 2015;29:2196–2202.
155. Nordholm-Carstensen A, Jensen KK, Krarup PM. Oncological outcome following laparoscopic versus open surgery for cancer in the transverse colon: a nationwide cohort study. *Surg Endosc.* 2018;32:4148–4157.
156. Wu Q, Wei M, Ye Z, et al. Laparoscopic colectomy versus open colectomy for treatment of transverse colon cancer: a systematic review and meta-analysis. *J Laparoendosc Adv Surg Tech A.* 2017;27:1038–1050.
157. Zeng WG, Liu MJ, Zhou ZX, et al. Outcome of Laparoscopic Versus Open Resection for Transverse Colon Cancer. *J Gastrointest Surg.* 2015;19:1869–1874.
158. Dong B, Luo Z, Lu J, et al. Single-incision laparoscopic versus conventional laparoscopic right colectomy: a systematic review and meta-analysis. *Int J Surg.* 2018;55:31–38.
159. Katsuno G, Fukunaga M, Nagakari K, Yoshikawa S, Azuma D, Kohama S. Short-term and long-term outcomes of single-incision versus multi-incision laparoscopic resection for colorectal cancer: a propensity-score-matched analysis of 214 cases. *Surg Endosc.* 2016;30:1317–1325.
160. Miyo M, Takemasa I, Ishihara H, et al. Long-term outcomes of single-site laparoscopic colectomy with complete mesocolic excision for colon cancer: comparison with conventional multiport laparoscopic colectomy using propensity score matching. *Dis Colon Rectum.* 2017;60:664–673.
161. Yun JA, Yun SH, Park YA, et al. Oncologic outcomes of single-incision laparoscopic surgery compared with conventional laparoscopy for colon cancer. *Ann Surg.* 2016;263:973–978.
162. Kang BM, Kim HJ, Kye BH, et al. Multicenter, randomized single-port versus multiport laparoscopic surgery (SIMPLE) trial in colon cancer: an interim analysis. *Surg Endosc.* 2018;32:1540–1549.
163. Watanabe J, Ota M, Fujii S, Suwa H, Ishibe A, Endo I. Randomized clinical trial of single-incision versus multiport laparoscopic colectomy. *Br J Surg.* 2016;103:1276–1281.
164. Chung CC, Ng DC, Tsang WW, et al. Hand-assisted laparoscopic versus open right colectomy: a randomized controlled trial. *Ann Surg.* 2007;246:728–733.
165. Ng LW, Tung LM, Cheung HY, Wong JC, Chung CC, Li MK. Hand-assisted laparoscopic versus total laparoscopic right colectomy: a randomized controlled trial. *Colorectal Dis.* 2012;14:e612–e617.
166. Sorbye H, Mauer M, Gruenberger T, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK (CRUK); Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). *Ann Surg.* 2012;255:534–539.
167. Gorgun E, Benlice C, Church JM. Does cancer risk in colonic polyps unsuitable for polypectomy support the need for advanced endoscopic resections? *J Am Coll Surg.* 2016;223:478–484.
168. Nakajima K, Sharma SK, Lee SW, Milsom JW. Avoiding colorectal resection for polyps: is CELS the best method? *Surg Endosc.* 2016;30:807–818.
169. Repici A, Hassan C, De Paula Pessoa D, et al. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review. *Endoscopy.* 2012;44:137–150.
170. Sanchez-Yague A, Kaltenbach T, Raju G, Soetikno R. Advanced endoscopic resection of colorectal lesions. *Gastroenterol Clin North Am.* 2013;42:459–477.
171. Williams JG, Pullan RD, Hill J, et al; Association of Coloproctology of Great Britain and Ireland. Management of the malignant colorectal polyp: ACPGBI position statement. *Colorectal Dis.* 2013;15 Suppl 2:1–38.
172. Butte JM, Tang P, Gonen M, et al. Rate of residual disease after complete endoscopic resection of malignant colonic polyp. *Dis Colon Rectum.* 2012;55:122–127.
173. Gill MD, Rutter MD, Holtham SJ. Management and short-term outcome of malignant colorectal polyps in the north of England(1). *Colorectal Dis.* 2013;15:169–176.
174. Richards CH, Ventham NT, Mansouri D, et al; Scottish Surgical Research Group. An evidence-based treatment algorithm for colorectal polyp cancers: results from the Scottish Screen-detected Polyp Cancer Study (SSPoCS). *Gut.* 2018;67:299–306.
175. Volk EE, Goldblum JR, Petras RE, Carey WD, Fazio VW. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. *Gastroenterology.* 1995;109:1801–1807.

176. Kikuchi R, Takano M, Takagi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. *Dis Colon Rectum*. 1995;38:1286–1295.
177. Yamamoto S, Watanabe M, Hasegawa H, et al. The risk of lymph node metastasis in T1 colorectal carcinoma. *Hepatogastroenterology*. 2004;51:998–1000.
178. Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. *Endoscopy*. 2013;45:827–834.
179. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. *Gastroenterology*. 1985;89:328–336.
180. Cooper HS, Deppisch LM, Gourley WK, et al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. *Gastroenterology*. 1995;108:1657–1665.
181. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. *Dis Colon Rectum*. 2002;45:200–206.
182. Hassan C, Zullo A, Risio M, Rossini FP, Morini S. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. *Dis Colon Rectum*. 2005;48:1588–1596.
183. Brown IS, Bettington ML, Bettington A, Miller G, Rosty C. Adverse histological features in malignant colorectal polyps: a contemporary series of 239 cases. *J Clin Pathol*. 2016;69:292–299.
184. Shaukat A, Kaltenbach T, Dominitz JA, et al. Endoscopic recognition and management strategies for malignant colorectal polyps: recommendations of the us multi-society task force on colorectal cancer. *Gastrointest Endosc*. 2020;92:997–1015.e1.
185. Hogan J, Samaha G, Burke J, et al. Emergency presenting colon cancer is an independent predictor of adverse disease-free survival. *Int Surg*. 2015;100:77–86.
186. Spannenburg L, Sanchez Gonzalez M, Brooks A, et al. Surgical outcomes of colonic stents as a bridge to surgery versus emergency surgery for malignant colorectal obstruction: A systematic review and meta-analysis of high quality prospective and randomised controlled trials. *Eur J Surg Oncol*. 2020;46:1404–1414.
187. Arezzo A, Passera R, Lo Secco G, et al. Stent as bridge to surgery for left-sided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: results of a systematic review and meta-analysis of randomized controlled trials. *Gastrointest Endosc*. 2017;86:416–426.
188. Sagar J. Colorectal stents for the management of malignant colonic obstructions. *Cochrane Database Syst Rev*. 2011;(11):CD007378.
189. Boland PA, Kelly ME, Donlon NE, et al. Outcomes following colonic stenting for malignant left-sided bowel obstruction: a systematic review of randomised controlled trials. *Int J Colorectal Dis*. 2019;34:1625–1632.
190. Huang X, Lv B, Zhang S, Meng L. Preoperative colonic stents versus emergency surgery for acute left-sided malignant colonic obstruction: a meta-analysis. *J Gastrointest Surg*. 2014;18:584–591.
191. Balciscueta I, Balciscueta Z, Uribe N, García-Granero E. Long-term outcomes of stent-related perforation in malignant colon obstruction: a systematic review and meta-analysis. *Int J Colorectal Dis*. 2020;35:1439–1451.
192. Veld JV, Amelung FJ, Borstlap WAA, et al; Dutch Snapshot Research Group. decompressing stoma as bridge to elective surgery is an effective strategy for left-sided obstructive colon cancer: a national, propensity-score matched study. *Ann Surg*. 2020;272:738–743.
193. Veld JV, Amelung FJ, Borstlap WAA, et al; Dutch Snapshot Research Group. Comparison of decompressing stoma vs stent as a bridge to surgery for left-sided obstructive colon cancer. *JAMA Surg*. 2020;155:206–215.
194. Morita S, Ikeda K, Komori T, et al. Outcomes in colorectal surgeon-driven management of obstructing colorectal cancers. *Dis Colon Rectum*. 2016;59:1028–1033.
195. Ji WB, Kwak JM, Kang DW, et al. Clinical benefits and oncologic equivalence of self-expandable metallic stent insertion for right-sided malignant colonic obstruction. *Surg Endosc*. 2017;31:153–158.
196. Kye BH, Lee YS, Cho HM, et al. Comparison of long-term outcomes between emergency surgery and bridge to surgery for malignant obstruction in right-sided colon cancer: a multicenter retrospective study. *Ann Surg Oncol*. 2016;23:1867–1874.
197. Sakamoto T, Fujiogi M, Lefor AK, Matsui H, Fushimi K, Yasunaga H. Stent as a bridge to surgery or immediate colectomy for malignant right colonic obstruction: propensity-scored, national database study. *Br J Surg*. 2020;107:1354–1362.
198. Boeding JRE, Ramphal W, Rijken AM, et al. A systematic review comparing emergency resection and staged treatment for curable obstructing right-sided colon cancer. *Ann Surg Oncol*. 2021;28:3545–3555.
199. Daniels M, Merkel S, Agaimy A, Hohenberger W. Treatment of perforated colon carcinomas-outcomes of radical surgery. *Int J Colorectal Dis*. 2015;30:1505–1513.
200. Zielinski MD, Merchea A, Heller SF, You YN. Emergency management of perforated colon cancers: how aggressive should we be? *J Gastrointest Surg*. 2011;15:2232–2238.
201. Cheynel N, Cortet M, Lepage C, Ortega-Debalon P, Faivre J, Bouvier AM. Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population. *Dis Colon Rectum*. 2009;52:406–411.
202. van Hooft JE, van Halsema EE, Vanbiervliet G, et al; European Society of Gastrointestinal Endoscopy. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy*. 2014;46:990–1053.
203. Feingold DL, Caliendo FJ, Chinn BT, et al. Does hemodynamic instability predict positive technetium-labeled red blood cell scintigraphy in patients with acute lower gastrointestinal bleeding? A review of 50 patients. *Dis Colon Rectum*. 2005;48:1001–1004.
204. García-Blázquez V, Vicente-Bártulos A, Olavarria-Delgado A, Plana MN, van der Winden D, Zamora J; EBM-Connect Collaboration. Accuracy of CT angiography in the diagnosis of acute gastrointestinal bleeding: systematic review and meta-analysis. *Eur Radiol*. 2013;23:1181–1190.
205. Olds GD, Cooper GS, Chak A, Sivak MV Jr, Chitale AA, Wong RC. The yield of bleeding scans in acute lower gastrointestinal hemorrhage. *J Clin Gastroenterol*. 2005;39:273–277.
206. Tabibian JH, Wong Kee Song LM, Enders FB, Aguet JC, Tabibian N. Technetium-labeled erythrocyte scintigraphy in acute gastrointestinal bleeding. *Int J Colorectal Dis*. 2013;28:1099–1105.

207. Koh DC, Luchtefeld MA, Kim DG, et al. Efficacy of transarterial embolization as definitive treatment in lower gastrointestinal bleeding. *Colorectal Dis*. 2009;11:53–59.
208. Green BT, Rockey DC, Portwood G, et al. Urgent colonoscopy for evaluation and management of acute lower gastrointestinal hemorrhage: a randomized controlled trial. *Am J Gastroenterol*. 2005;100:2395–2402.
209. Elferink MA, Visser O, Wiggers T, et al. Prognostic factors for locoregional recurrences in colon cancer. *Ann Surg Oncol*. 2012;19:2203–2211.
210. Liska D, Stocchi L, Karagkounis G, et al. Incidence, patterns, and predictors of locoregional recurrence in colon cancer. *Ann Surg Oncol*. 2017;24:1093–1099.
211. Wisselink DD, Klaver CEL, Hompes R, Bemelman WA, Tanis PJ. Curative-intent surgery for isolated locoregional recurrence of colon cancer: review of the literature and institutional experience. *Eur J Surg Oncol*. 2020;46:1673–1682.
212. Chesney TR, Nadler A, Acuna SA, Swallow CJ. Outcomes of resection for locoregionally recurrent colon cancer: a systematic review. *Surgery*. 2016;160:54–66.
213. Hallet J, Zih FS, Lemke M, Milot L, Smith AJ, Wong CS. Neoadjuvant chemoradiotherapy and multivisceral resection to optimize R0 resection of locally recurrent adherent colon cancer. *Eur J Surg Oncol*. 2014;40:706–712.
214. Jarrar A, Sheth R, Tiernan J, et al. Curative intent resection for loco-regionally recurrent colon cancer: Cleveland clinic experience. *Am J Surg*. 2020;219:419–423.
215. Harji DP, Sagar PM, Boyle K, Griffiths B, McArthur DR, Evans M. Surgical resection of recurrent colonic cancer. *Br J Surg*. 2013;100:950–958.
216. Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). *Ann Oncol*. 2014;25:1018–1025.
217. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. *J Clin Oncol*. 2013;31:1931–1938.
218. Kemeny NE, Chou JF, Boucher TM, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. *J Surg Oncol*. 2016;113:477–484.
219. Hernández J, Molins L, Fibla JJ, Heras F, Embún R, Rivas JJ; Grupo Español de Metástasis Pulmonares de Carcinoma Colorectal (GECMP-CCR) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR). *Ann Oncol*. 2016;27:850–855.
220. Lan YT, Jiang JK, Chang SC, et al. Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams. *Int J Colorectal Dis*. 2016;31:403–411.
221. Lordan JT, Karanjia ND, Quiney N, Fawcett WJ, Worthington TR. A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. *Eur J Surg Oncol*. 2009;35:302–306.
222. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet*. 2008;371:1007–1016.
223. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2013;14:1208–1215.
224. Tomaseo G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. *JAMA Oncol*. 2017;3:e170278.
225. Modest DP, Denecke T, Pratschke J, et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. *Eur J Cancer*. 2018;88:77–86.
226. Bolhuis K, Kos M, van Oijen MGH, Swijnenburg RJ, Punt CJA. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. *Eur J Cancer*. 2020;141:225–238.
227. Lévi FA, Boige V, Hebbar M, et al; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International). Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. *Ann Oncol*. 2016;27:267–274.
228. D'Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. *Ann Surg*. 2015;261:353–360.
229. Pak LM, Kemeny NE, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. *J Surg Oncol*. 2018;117:634–643.
230. Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. *J Am Coll Surg*. 2003;197:233–241.
231. Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. *Ann Surg Oncol*. 2007;14:3481–3491.
232. Shubert CR, Habermann EB, Bergquist JR, et al. An NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of colorectal resection. *J Gastrointest Surg*. 2015;19:1982–1994.
233. Silberhumer GR, Paty PB, Temple LK, et al. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. *Am J Surg*. 2015;209:935–942.
234. Renaud S, Seitlinger J, Lawati YA, et al. Anatomical resections improve survival following lung metastasectomy of

- colorectal cancer harboring KRAS mutations. *Ann Surg*. 2019;270:1170–1177.
235. Shiono S, Okumura T, Boku N, et al. Outcomes of segmentectomy and wedge resection for pulmonary metastases from colorectal cancer. *Eur J Cardiothorac Surg*. 2017;51:504–510.
 236. Suzuki H, Kiyoshima M, Kitahara M, Asato Y, Amemiya R. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer. *Ann Thorac Surg*. 2015;99:435–440.
 237. Milosevic M, Edwards J, Tsang D, et al. Pulmonary metastasectomy in colorectal cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed. *Colorectal Dis*. 2020;22:1314–1324.
 238. Kanzaki R, Suzuki O, Kanou T, et al. The short-term outcomes of pulmonary metastasectomy or stereotactic body radiation therapy for pulmonary metastasis from epithelial tumors. *J Cardiothorac Surg*. 2020;15:43.
 239. Hompes D, D'Hoore A, Van Cutsem E, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. *Ann Surg Oncol*. 2012;19:2186–2194.
 240. Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin c for HIPEC in colorectal cancer peritoneal carcinomatosis. *Eur J Surg Oncol*. 2017;43:144–149.
 241. Zani S, Papalezova K, Stinnett S, Tyler D, Hsu D, Blazer DG III. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. *J Surg Oncol*. 2013;107:307–311.
 242. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. *J Clin Oncol*. 2012;30:263–267.
 243. Razenberg LG, van Gestel YR, Lemmens VE, de Hingh IH, Creemers GJ. Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study. *Clin Colorectal Cancer*. 2016;15:e41–e46.
 244. Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. *Ann Surg Oncol*. 2007;14:509–514.
 245. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. *J Clin Oncol*. 2009;27:681–685.
 246. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. *Cancer*. 2010;116:3756–3762.
 247. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol*. 2008;15:2426–2432.
 248. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol*. 2005;12:65–71.
 249. Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. *Eur J Cancer*. 2016;53:155–162.
 250. Bakkers C, van Erning FN, Rovers KP, et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study. *Eur J Surg Oncol*. 2020;46(10 Pt A):1902–1907.
 251. Ihemelandu C, Fernandez S, Sugarbaker PH. A prognostic model for predicting overall survival in patients with peritoneal surface malignancy of an appendiceal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*. 2017;24:2266–2272.
 252. Quénet F, Elias D, Roca L, et al.; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021;22:256–266.
 253. Chicago Consensus Working Group. The Chicago consensus on peritoneal surface malignancies: management of colorectal metastases. *Ann Surg Oncol*. 2020;27:1761–1767.
 254. McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. *J Clin Oncol*. 2012;30:3223–3228.
 255. Lorimer PD, Motz BM, Kirks RC, et al. Frequency of unplanned surgery in patients with stage IV colorectal cancer receiving palliative chemotherapy with an intact primary: an analysis of SEER-Medicare. *J Surg Oncol*. 2019;120:407–414.
 256. Alawadi Z, Phatak UR, Hu CY, et al. Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer. *Cancer*. 2017;123:1124–1133.
 257. Kanemitsu Y, Shitara K, Mizusawa J, et al.; JCOG Colorectal Cancer Study Group. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (jco1007; ipacs): a randomized clinical trial. *J Clin Oncol*. 2021;39:1098–1107.
 258. Ahmed S, Fields A, Pahwa P, et al. Surgical resection of primary tumor in asymptomatic or minimally symptomatic patients with stage iv colorectal cancer: a Canadian province experience. *Clin Colorectal Cancer*. 2015;14:e41–e47.
 259. Shida D, Hamaguchi T, Ochiai H, et al. Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer: using a propensity score analysis. *Ann Surg Oncol*. 2016;23:3602–3608.
 260. Simillis C, Kalakouti E, Afxentiou T, et al. Primary tumor resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis. *World J Surg*. 2019;43:1829–1840.
 261. van Rooijen KL, Shi Q, Goey KKH, et al. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: individual patient data analysis of first-line randomised trials from the ARCAD database. *Eur J Cancer*. 2018;91:99–106.
 262. Park EJ, Baek JH, Choi GS, et al. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: a multicenter randomized controlled trial. *Cancers (Basel)*. 2020;12:E2306.

263. Fiori E, Lamazza A, Schillaci A, et al. Palliative management for patients with subacute obstruction and stage IV unresectable rectosigmoid cancer: colostomy versus endoscopic stenting: final results of a prospective randomized trial. *Am J Surg*. 2012;204:321–326.
264. Gianotti L, Tamini N, Nespoli L, et al. A prospective evaluation of short-term and long-term results from colonic stenting for palliation or as a bridge to elective operation versus immediate surgery for large-bowel obstruction. *Surg Endosc*. 2013;27:832–842.
265. Finlayson A, Hulme-Moir M. Palliative colonic stenting: a safe alternative to surgery in stage IV colorectal cancer. *ANZ J Surg*. 2016;86:773–777.
266. Young CJ, De-Loyde KJ, Young JM, et al. Improving quality of life for people with incurable large-bowel obstruction: randomized control trial of colonic stent insertion. *Dis Colon Rectum*. 2015;58:838–849.
267. Faraz S, Salem SB, Schattner M, et al. Predictors of clinical outcome of colonic stents in patients with malignant large-bowel obstruction because of extracolonic malignancy. *Gastrointest Endosc*. 2018;87:1310–1317.
268. Park JJ, Rhee K, Yoon JY, et al. Impact of peritoneal carcinomatosis on clinical outcomes of patients receiving self-expandable metal stents for malignant colorectal obstruction. *Endoscopy*. 2018;50:1163–1174.
269. Park YE, Park Y, Park SJ, Cheon JH, Kim WH, Kim TI. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. *Surg Endosc*. 2019;33:1225–1234.
270. van den Berg MW, Ledebuer M, Dijkgraaf MG, Fockens P, ter Borg F, van Hooft JE. Long-term results of palliative stent placement for acute malignant colonic obstruction. *Surg Endosc*. 2015;29:1580–1585.
271. Watt AM, Faragher IG, Griffin TT, Rieger NA, Maddern GJ. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. *Ann Surg*. 2007;246:24–30.
272. Yoon JY, Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Outcomes of secondary stent-in-stent self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc*. 2011;74:625–633.
273. Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Outcomes of secondary self-expandable metal stents versus surgery after delayed initial palliative stent failure in malignant colorectal obstruction. *Digestion*. 2013;88:46–55.
274. Abelson JS, Yeo HL, Mao J, Milsom JW, Sedrakyan A. Long-term postprocedural outcomes of palliative emergency stenting vs stoma in malignant large-bowel obstruction. *JAMA Surg*. 2017;152:429–435.
275. Lee JH, Emelogu I, Kukreja K, et al. Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab. *Gastrointest Endosc*. 2019;90:116–124.
276. van Halsema EE, van Hooft JE, Small AJ, et al. Perforation in colorectal stenting: a meta-analysis and a search for risk factors. *Gastrointest Endosc*. 2014;79:970–982.e7; quiz 983.e2, 983.e5.
277. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to braf mutation and mismatch repair status of the MOSAIC Study. *J Clin Oncol*. 2015;33:4176–4187.
278. Costas-Chavarri A, Nandakumar G, Temin S, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. *J Glob Oncol*. 2019;5:1–19.
279. Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. *Cancer*. 2015;121:527–534.
280. Labianca R, Nordlinger B, Beretta GD, et al; ESMO Guidelines Working Group. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24(suppl 6):vi64–vi72.
281. Liebig C, Ayala G, Wilks J, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. *J Clin Oncol*. 2009;27:5131–5137.
282. Niedzwiecki D, Bertagnolli MM, Warren RS, et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. *J Clin Oncol*. 2011;29:3146–3152.
283. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. *Dis Colon Rectum*. 2008;51:503–507.
284. Romiti A, Roberto M, Marchetti P, et al. Study of histopathologic parameters to define the prognosis of stage II colon cancer. *Int J Colorectal Dis*. 2019;34:905–913.
285. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol*. 2010;28:3219–3226.
286. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. *J Clin Oncol*. 2007;25:2198–2204.
287. André T, Boni C, Mounedji-Boudiaf L, et al.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*. 2004;350:2343–2351.
288. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet*. 2007;370:2020–2029.
289. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. *Ann Surg Oncol*. 2010;17:959–966.
290. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009;27:3109–3116.
291. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. *J Clin Oncol*. 2012;30:3353–3360.
292. Shah MA, Renfro LA, Allegra CJ, et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin

- benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. *J Clin Oncol*. 2016;34:843–853.
293. Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. *Cancer*. 2016;122:3277–3287.
 294. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. *J Natl Cancer Inst*. 2012;104:211–227.
 295. Schmoll HJ, Twelves C, Sun W, et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. *Lancet Oncol*. 2014;15:1481–1492.
 296. Tougeron D, Mouillet G, Trouilloud I, et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. *J Natl Cancer Inst*. 2016;108:108.
 297. Schmoll HJ, Taberero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the no16968 randomized controlled phase III trial. *J Clin Oncol*. 2015;33:3733–3740.
 298. Grothey A. Oxaliplatin-safety profile: neurotoxicity. *Semin Oncol*. 2003;30(4 Suppl 15):5–13.
 299. Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. *N Engl J Med*. 2018;378:1177–1188.
 300. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. *J Clin Oncol*. 2007;25:3456–3461.
 301. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. *J Clin Oncol*. 2009;27:3117–3125.
 302. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). *Ann Oncol*. 2009;20:674–680.
 303. Papadimitriou CA, Papakostas P, Karina M, et al. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. *BMC Med*. 2011;9:10.
 304. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA*. 2012;307:1383–1393.
 305. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. *Lancet Oncol*. 2012;13:1225–1233.
 306. André T, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med*. 2020;383:2207–2218.
 307. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (checkmate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2017;18:1182–1191.
 308. Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. *J Clin Oncol*. 2020;38:11–19.
 309. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015;372:2509–2520.
 310. Turner MC, Farrow NE, Rhodin KE, et al. Delay in Adjuvant Chemotherapy and Survival Advantage in Stage III Colon Cancer. *J Am Coll Surg*. 2018;226:670–678.
 311. Sun Z, Adam MA, Kim J, et al. Determining the optimal timing for initiation of adjuvant chemotherapy after resection for stage II and III colon cancer. *Dis Colon Rectum*. 2016;59:87–93.
 312. Bos AC, van Erning FN, van Gestel YR, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. *Eur J Cancer*. 2015;51:2553–2561.
 313. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. *J Clin Oncol*. 2010;28:3937–3944.
 314. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. *J Clin Oncol*. 2013;31:1775–1781.
 315. Yothers G, O'Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. *J Clin Oncol*. 2013;31:4512–4519.
 316. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. *J Clin Oncol*. 2011;29:4611–4619.
 317. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. *J Clin Oncol*. 2011;29:17–24.
 318. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. *J Clin Oncol*. 2011;29:4620–4626.
 319. Niedzwiecki D, Frankel WL, Venook AP, et al. Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (Alliance). *J Clin Oncol*. 2016;34:3047–3053.
 320. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. *N Engl J Med*. 2016;374:211–222.
 321. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in

- patients with stages I to III colorectal cancer. *JAMA Oncol.* 2019;5:1124–1131.
322. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. *Sci Transl Med.* 2016;8:346ra92.
323. Chakrabarti S, Xie H, Urrutia R, Mahipal A. The promise of circulating tumor DNA (ctDNA) in the management of early-stage colon cancer: a critical review. *Cancers (Basel).* 2020;12:E2808.
324. Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. *Ann Oncol.* 2019;30:1804–1812.
325. Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. *JAMA Oncol.* 2019;5:1710–1717.
326. Berger AW, Schwerdel D, Welz H, et al. Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. *PLoS One.* 2017;12:e0174308.
327. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med.* 2008;14:985–990.
328. Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. *Ann Oncol.* 2015;26:1715–1722.